{"title":"WEIGHT LOSS","description":"","products":[{"product_id":"ipamorelin-5mg","title":"(🔥 Fat loss) Ipamorelin Peptide - 5mg - 10 Vials","description":"\u003cdiv class=\"et_pb_tab_content\"\u003e\n\u003cdiv class=\"pro-description-con\"\u003e\n\u003cp\u003e🧬 What is Ipamorelin?\u003c\/p\u003e\n\u003cp\u003eIpamorelin is a highly selective GHRP:\u003c\/p\u003e\n\u003cp\u003e👉 Acts on ghrelin receptors\u003cbr\u003e👉 Triggers the pituitary gland to release GH\u003cbr\u003e👉 Has minimal impact on other hormones (compared to older-generation GHRPs)\u003c\/p\u003e\n\u003cp\u003e💪 Why is it popular in the fitness community?\u003c\/p\u003e\n\u003cp\u003eMany consider it a “cleaner GH booster.” Common goals include:\u003c\/p\u003e\n\u003cp\u003e🔥 Fat loss\u003cbr\u003e💪 Muscle-building support\u003cbr\u003e😴 Improved sleep quality\u003cbr\u003e🩹 Faster recovery\u003cbr\u003e⚡ Enhanced training adaptation\u003c\/p\u003e\n\u003cp\u003eIt is often combined with:\u003c\/p\u003e\n\u003cp\u003eMod GRF 1-29 (CJC-1295 NO DAC)\u003c\/p\u003e\n\u003cp\u003e(a classic stack).\u003c\/p\u003e\n\u003cp\u003e🧠 How It Works (Simplified Version)\u003c\/p\u003e\n\u003cp\u003eIpamorelin → Mimics “hunger signals” → Stimulates the pituitary gland:\u003c\/p\u003e\n\u003cp\u003e➡️ Secretes GH (growth hormone)\u003cbr\u003e➡️ Increases IGF-1 (indirectly)\u003c\/p\u003e\n\u003cp\u003eBut its key features are:\u003cbr\u003e✔ Minimal impact on cortisol\u003cbr\u003e✔ Minimal impact on prolactin\u003cbr\u003e✔ Minimal impact on appetite (milder than GHRP-6)\u003c\/p\u003e\n\u003cp\u003eTherefore, it is considered “cleaner.”\u003c\/p\u003e\n\u003cp\u003e😴 Most Common User Feedback (Based on Experience)\u003c\/p\u003e\n\u003cp\u003eMany users report:\u003c\/p\u003e\n\u003cp\u003eDeeper sleep 😴\u003cbr\u003eFaster recovery 💪\u003cbr\u003eReduced post-workout soreness 🩹\u003cbr\u003eTighter physique 🔥\u003cbr\u003eEnhanced sense of recovery overnight\u003c\/p\u003e\n\u003ch3\u003e\u003cbr\u003e\u003c\/h3\u003e\n\u003ch3\u003eIpamorelin Peptide\u003c\/h3\u003e\n\u003cp class=\"white-back-d\" style=\"margin-bottom: 30px;\"\u003eIpamorelin is a small pentapeptide that binds to the receptor of ghrelin\/growth hormone secretagogue (GHS), and is speculated to trigger the release of growth hormone via pituitary cells. Research has suggested the peptide to be selective in its mode of action.\u003csup\u003e[1]\u003c\/sup\u003e Ipamorelin, researchers report, does not appear to induce non-specific release of hormones like prolactin, thyroid-stimulating hormone, ACTH, luteinizing hormone, follicle-stimulating hormone, or cortisol. The high specificity of the peptide makes it an ideal model for the study of selectivity in receptor binding. It appears to function through interaction with cognate receptors on the target cell surface and mediates a cellular response. Ipamorelin may induce secretions from the pituitary gland, promoting growth in animal study models.\u003csup\u003e[2]\u003c\/sup\u003e In addition, it may not only trigger the expression of insulin-like growth factor-1(IGF-1) but may also inhibit the secretion of somatostatin. IGF-1 is considered to be the main anabolic mediator of growth hormone.\u003c\/p\u003e\n\u003ch3\u003eSpecifications\u003c\/h3\u003e\n\u003cp class=\"grey-back\"\u003e\u003cstrong\u003eMolecular Formula:\u003c\/strong\u003e C\u003csub\u003e38\u003c\/sub\u003eH\u003csub\u003e49\u003c\/sub\u003eN\u003csub\u003e9\u003c\/sub\u003eO\u003csub\u003e5\u003c\/sub\u003e\u003c\/p\u003e\n\u003cp class=\"white-back\"\u003e\u003cstrong\u003eMolecular Weight:\u003c\/strong\u003e 711.86 g\/mol\u003c\/p\u003e\n\u003cp class=\"grey-back\" style=\"margin-bottom: 30px;\"\u003e\u003cstrong\u003eSequence:\u003c\/strong\u003e Aib-His-D-2Nal-D-Phe-Lys-NH2\u003c\/p\u003e\n\u003ch3\u003eIpamorelin Research\u003c\/h3\u003e\n\u003cp class=\"white-back-d\"\u003e\u003cstrong\u003eIpamorelin and The Growth Hormone Secretagogue Receptors\u003c\/strong\u003e\u003cbr\u003eIpamorelin may be a growth hormone secretagogue receptor agonist stimulating endogenous growth hormone (hGH) release. More specifically, Ipamorelin is classified as a growth hormone secretagogue receptor 1a (GHS-R1a), also the receptor for the endogenous hormone ghrelin. Ghrelin is known as the hunger hormone and appears to also regulate hGH release by activating the GHS-R1a in pituitary cells.\u003csup\u003e[3] \u003c\/sup\u003eIn vitro experiments indicate that Ipamorelin's interaction with the Growth Hormone Secretagogue Receptor type 1a (GHS-R1a) might influence the somatotroph cells located in the anterior segment of the pituitary gland.\u003csup\u003e[4]\u003c\/sup\u003e This potential influence is thought to initiate a cascade of cellular signaling mechanisms. A key component in this signaling cascade is phospholipase C (PLC), a crucial enzyme that, according to some scientific hypotheses, may facilitate the production of inositol triphosphate (IP3) and diacylglycerol (DAG). The emergence of these secondary messenger molecules, particularly IP3, may stimulate the release of calcium ions (Ca2+) from the cell’s internal reserves. Concurrently, DAG is believed to potentially activate protein kinase C (PKC), a family of enzymes believed to play significant roles in various cellular functions. The hypothesized increase in calcium ion concentration within the cells, along with the potential activation of PKC, might lead to the exocytosis of vesicles that contain growth hormones. Research in clinical settings has suggested that exposure to Ipamorelin may cause notable increases in hGH synthesis by these pituitary cells. Specifically, Ipamorelin was observed to elevate growth hormone concentrations up to approximately 80 milli-international units per liter (mIU\/l), which is about 26.6 nanograms per milliliter (ng\/ml). Comparatively, when these increases are quantified against a placebo baseline of 1.31 mIU\/l or 0.4 ng\/ml, there seems to be an enhancement that might exceed 60 times the baseline levels.\u003csup\u003e[5]\u003c\/sup\u003e\u003c\/p\u003e\n\u003cp class=\"grey-back-d\"\u003e\u003cstrong\u003eIpamorelin and the Musculoskeletal System\u003c\/strong\u003e\u003cbr\u003eLessened bone density over prolonged periods may lead to fracture. Ipamorelin studies in rats have observed that the peptide may prevent bone loss following prolonged glucocorticoid exposure, and also may induce up to a four-fold increase in bone formation.\u003csup\u003e[6]\u003c\/sup\u003e The researchers also reported that \u003cem\u003e“the decrease in muscle strength and bone formation found in GC-rats was counteracted by simultaneous administration of the growth hormone secretagogue.”\u003c\/em\u003e The peptide may potentially improve the bone mineral density of both existing and new bones. Further research suggests that the peptide may potentially activate osteoblasts—cells crucial for bone formation—through mechanisms mediated by hGH, which might enhance their proliferation, growth, and differentiation. In specific research, mouse models were subjected to exposure with either Ipamorelin or a control.\u003csup\u003e[7]\u003c\/sup\u003e The actions of Ipamorelin on the bone mineral density of these mice were diligently observed using real-time dual X-ray absorptiometry (DEXA), focusing on critical areas such as the femur and the L6 vertebra. Following the trial, the femur samples underwent additional analysis with mid-diaphyseal peripheral quantitative computed tomography (pQCT) scans. Early results suggested that the peptide might have contributed to an increase in body mass and possibly raised the bone mineral content (BMC) in the tibia and vertebrae, as indicated by DEXA measurements, compared to the control group. Moreover, data from pQCT scans tentatively indicated that the noted increase in cortical BMC might be related to an increase in the cross-sectional area of the bone.\u003csup\u003e[7]\u003c\/sup\u003e Additionally, Ipamorelin may possibly mitigate or reverse ancillary impacts such as muscle wasting and fat deposition in visceral organs.\u003csup\u003e[6]\u003c\/sup\u003e\u003c\/p\u003e\n\u003cp class=\"white-back-d\"\u003e\u003cstrong\u003eIpamorelin and Diabetes\u003c\/strong\u003e\u003cbr\u003eStudies in murine models of diabetes have suggested an efficacy of Ipamorelin in promoting insulin release from islet cells of the pancreas.\u003csup\u003e[8]\u003c\/sup\u003e Studies suggest that the peptide may mediate the release of insulin through the indirect excitation of calcium channels found on the islet cells. The hypothesized mechanism of Ipamorelin action highlights the limitations of type 2 diabetes and further study may be of interest to researchers.\u003c\/p\u003e\n\u003cp class=\"grey-back-d\"\u003e\u003cstrong\u003eIpamorelin and Muscle Cells\u003c\/strong\u003e\u003cbr\u003eGlucocorticoids are the kind of corticosteroids that are commonly considered to exert an anti-inflammatory response in diverse conditions ranging from cancer to autoimmune disease. Ancillary action has also been reported. Over long durations, a higher concentration of hormones may be required to overcome physiological ancillary impacts. Researchers studying the action of Ipamorelin have suggested the peptide’s potential to decrease certain unintended impacts associated with glucocorticoid exposure. More specifically, studies on Ipamorelin posit that it may help to reestablish the nitrogen balance and reduce nitrogen wasting in the liver of rats exposed to glucocorticoids.\u003csup\u003e[9]\u003c\/sup\u003e The observed actions might tentatively be attributed to Ipamorelin's potential in modulating hGH and subsequently IGF-1 production. The research primarily examined the liver’s ability to generate urea-N (CUNS), which indicates the liver's efficacy in nitrogen metabolism. The analysis included a detailed examination of the levels of messenger RNA (mRNA) for enzymes involved in the liver's urea cycle. Additionally, the study explored overall nitrogen homeostasis and proposed theoretical distributions of nitrogen among various body organs. The results tentatively indicate that Ipamorelin may lead to an approximate 20% decrease in CUNS when compared to conditions of artificially induced catabolism. Moreover, there is a potential reduction in the expression of enzymes responsible for the urea cycle, a possible re-establishment of nitrogen equilibrium, and a hypothetical modification or enhancement of nitrogen levels in different tissues.\u003csup\u003e[9]\u003c\/sup\u003e\u003c\/p\u003e\n\u003cp class=\"white-back-d\"\u003e\u003cstrong\u003eIpamorelin as Ghrelin Receptor Probe\u003c\/strong\u003e\u003cbr\u003eThe peptide appears to bind strongly to the ghrelin receptor and may act as a selective agonist. Interestingly, the ghrelin receptor has been observed to increase cardiac failure and certain types of cancer, including carcinomas. Researchers have proposed studying Ipamorelin as a probe in positron emission tomography (PET) scans to help diagnose research models. \u003csup\u003e[10]\u003c\/sup\u003e Further research is ongoing.\u003c\/p\u003e\n\u003cp class=\"grey-back-d\" style=\"margin-bottom: 30px;\"\u003e\u003cstrong\u003eIpamorelin and Food Intake\u003c\/strong\u003e\u003cbr\u003eIpamorelin has been studied in multiple proof-of-concept studies to determine its potential to reduce Post Operative Ilius (POI). It was found to shorten the time of uptake of the first meal by about 12 hours.\u003csup\u003e[11]\u003c\/sup\u003e The researchers concluded that \u003cem\u003e“Ipamorelin accelerates gastric emptying in a rodent model of postoperative ileus through the stimulation of gastric contractility by activating a ghrelin receptor-mediated mechanism involving cholinergic excitatory neurons.”\u003c\/em\u003e Some of the research observations in this and other studies suggest that residual radiolabeled food remaining in the stomach of rats with POI was less after the influence of Ipamorelin, even when compared to rats without POI. Thus it may be posited that Ipamorelin may speed up the passage of food through the digestive system, following food intake.\u003cbr\u003e\u003cbr\u003eOn top of that, some researchers suggest that Ipamorelin may also influence the total intake of food through its potential action via the ghrelin receptors in the nervous system.\u003csup\u003e[12] \u003c\/sup\u003eGhrelin receptors are known for their role in controlling appetite, and their activation may lead to heightened hunger cues, potentially resulting in increased body mass. It has been observed in some experimental setups that animal subjects exposed to Ipamorelin experienced an approximate 15% increase in body weight. In these studies, the augmented body weight might correlate with an increase in adipose tissue mass relative to overall body mass. Adipose tissue, or body fat, contributes to energy storage and hormone regulation. Dual-energy X-ray absorptiometry (DEXA) scans, which measure bone mineral density and body composition, might potentially exhibit an elevated body fat percentage as a result of Ipamorelin. Consequently the researchers posited that \"\u003cem\u003eGHSs increase body fat by GH-independent mechanisms that may include increased feeding.\u003c\/em\u003e”\u003csup\u003e[12]\u003c\/sup\u003e\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003ch3 style=\"color: #555;\"\u003eReferences\u003c\/h3\u003e\n\u003cdiv class=\"white-back-d\" style=\"padding-bottom: 5px !important; margin-bottom: 25px !important;\"\u003e\n\u003col style=\"color: #555;\"\u003e\n\u003cli\u003eRaun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998 Nov;139(5):552-61. . PMID: 9849822.\u003c\/li\u003e\n\u003cli\u003eJohansen PB, Nowak J, Skjaerbaek C, Flyvbjerg A, Andreassen TT, Wilken M, Orskov H. Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats. Growth Horm IGF Res. 1999 Apr;9(2):106-13. . PMID: 10373343.\u003c\/li\u003e\n\u003cli\u003eSinha DK, Balasubramanian A, Tatem AJ, Rivera-Mirabal J, Yu J, Kovac J, Pastuszak AW, Lipshultz LI. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Transl Androl Urol. 2020 Mar;9(Suppl 2):S149-S159. doi: 10.21037\/tau.2019.11.30. PMID: 32257855; PMCID: PMC7108996\u003c\/li\u003e\n\u003cli\u003eJiménez-Reina, L., Cañete, R., de la Torre, M. J., \u0026amp; Bernal, G. (2002). Influence of chronic treatment with the growth hormone secretagogue Ipamorelin, in young female rats: somatotroph response in vitro. Histology and histopathology, 17(3), 707–714.\u003c\/li\u003e\n\u003cli\u003eGobburu, J.V.S., Agersø, H., Jusko, W.J. et al. Pharmacokinetic-Pharmacodynamic Modeling of Ipamorelin, a Growth Hormone Releasing Peptide, in Human Volunteers. Pharm Res 16, 1412–1416 (1999).\u003c\/li\u003e\n\u003cli\u003eAndersen NB, Malmlöf K, Johansen PB, Andreassen TT, Ørtoft G, Oxlund H. The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats. Growth Horm IGF Res. 2001 Oct;11(5):266-72. . PMID: 11735244.\u003c\/li\u003e\n\u003cli\u003eSvensson, J., Lall, S., Dickson, S. L., Bengtsson, B. A., Rømer, J., Ahnfelt-Rønne, I., Ohlsson, C., \u0026amp; Jansson, J. O. (2000). The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats. \u003cem\u003eThe Journal of endocrinology\u003c\/em\u003e, \u003cem\u003e165\u003c\/em\u003e(3), 569–577.\u003c\/li\u003e\n\u003cli\u003eAdeghate E, Ponery AS. Mechanism of ipamorelin-evoked insulin release from the pancreas of normal and diabetic rats. Neuro Endocrinol Lett. 2004 Dec;25(6):403-6. PMID: 15665799.\u003c\/li\u003e\n\u003cli\u003eAagaard, N. K., Grøfte, T., Greisen, J., Malmlöf, K., Johansen, P. B., Grønbaek, H., Ørskov, H., Tygstrup, N., \u0026amp; Vilstrup, H. (2009). Growth hormone and growth hormone secretagogue effects on nitrogen balance and urea synthesis in steroid treated rats. \u003cem\u003eGrowth hormone \u0026amp; IGF research: official journal of the Growth Hormone Research Society and the International IGF Research Society\u003c\/em\u003e, \u003cem\u003e19\u003c\/em\u003e(5), 426–431.\u003c\/li\u003e\n\u003cli\u003eChilds MD, Luyt LG. A Decade’s Progress in the Development of Molecular Imaging Agents Targeting the Growth Hormone Secretagogue Receptor. Mol Imaging. 2020 Jan-Dec;19:1536012120952623. . PMID: 33104445; PMCID: PMC8865914.\u003c\/li\u003e\n\u003cli\u003eGreenwood-Van Meerveld B, Tyler K, Mohammadi E, Pietra C. Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus. J Exp Pharmacol. 2012 Oct 19;4:149-55. . PMID: 27186127; PMCID: PMC4863553.\u003c\/li\u003e\n\u003cli\u003eLall, S., Tung, L. Y., Ohlsson, C., Jansson, J. O., \u0026amp; Dickson, S. L. (2001). Growth hormone (GH)-independent stimulation of adiposity by GH secretagogues. Biochemical and biophysical research communications, 280(1), 132–138.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"author-details\"\u003e\n\u003ch2\u003e\u003ca href=\"https:\/\/biotechpeptides.com\/dr-marinov\/\"\u003eDr. Usman\u003c\/a\u003e\u003c\/h2\u003e\n\u003cp\u003eDr. Usman (BSc, MBBS, MaRCP) completed his studies in medicine at the Royal College of Physicians, London. He is an avid researcher with more than 30 publications in internationally recognized peer-reviewed journals. Dr. Usman has worked as a researcher and a medical consultant for reputable pharmaceutical companies such as Johnson \u0026amp; Johnson and Sanofi.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"mysite","offers":[{"title":"Default Title","offer_id":51786428612925,"sku":"sku2194756137677","price":150.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0997\/4474\/3741\/files\/IPAMORELIN-5MG-2-1.webp?v=1780466144"},{"product_id":"mod-grf-1-29-5mg-cjc-1295-no-dac","title":"(🔥 Fat loss+💪 Recovery) Mod GRF 1-29 (CJC-1295 NO DAC) (5mg) - 10 Vials","description":"\u003cdiv class=\"et_pb_tab_content\"\u003e\n\u003cdiv class=\"pro-description-con\"\u003e\n\u003ch3\u003e🔥 Fat loss\u003cbr\u003e💪 Recovery\u003cbr\u003e😴 Improved sleep\u003cbr\u003e🩹 Post-workout recovery\u003cbr\u003e📈 Increased IGF-1\u003cbr\u003eDeeper sleep\u003cbr\u003eGreater sense of recovery\u003cbr\u003eBetter post-workout condition\u003cbr\u003eIncreased night sweats\u003cbr\u003eChanges in hunger\u003c\/h3\u003e\n\u003ch3\u003e\u003cbr\u003e\u003c\/h3\u003e\n\u003ch3\u003eModified GRF (1-29) Peptide\u003c\/h3\u003e\n\u003cp style=\"margin-bottom: 30px;\" class=\"white-back-d\"\u003eModified GRF (1-29), or Mod GRF (1-29), is a synthetic peptide that is a modified fragment of the endogenously occurring growth hormone-releasing hormone (GHRH). It was first developed in the 1980s when studies indicated that the first 29 amino acids of GHRH may possess all of the biological potential associated with the full-length 44 GHRH molecule.\u003csup\u003e[1]\u003c\/sup\u003e\u003cbr\u003e\u003cbr\u003eThis discovery led to the development of a truncated version called GRF (1-29), also referred to as by researchers. Mod GRF (1-29) introduces specific modifications to support the peptide's stability and efficacy. Four amino acids in the sequence are substituted at positions 2, 8, 15, and 27.\u003csup\u003e[2]\u003c\/sup\u003e Here is what some researchers believe about these modifications:\u003cbr\u003e- Position 2: The amino acid alanine is replaced with its mirror image, D-alanine. This substitution aims to increase resistance to enzymatic degradation, thereby improving the peptide's stability.\u003cbr\u003e- Position 8: Asparagine is substituted with lysine, an amino acid with a positively charged side chain. This change may support the peptide's binding affinity to GHRH receptors, potentially increasing its biological activity.\u003cbr\u003e- Position 15: Histidine is replaced with D-phenylalanine, another D-amino acid. This modification is intended to protect the peptide from further enzymatic breakdown.\u003cbr\u003e- Position 27: Cysteine is substituted with N-methylglycine, also referred to as sarcosine. This alteration may extend the peptide's half-life by mitigating enzymatic cleavage.\u003cbr\u003e\u003cbr\u003eThese modifications collectively aim to produce a peptide with increased stability, a longer half-life, and better-supported interaction with GHRH receptors compared to the original GRF (1-29). Modified GRF (1-29) is structurally identical to CJC-1295 without DAC. The DAC in CJC-1295 serves to modify its pharmacokinetic properties.\u003c\/p\u003e\n\u003ch3\u003eSpecifications\u003c\/h3\u003e\n\u003cp class=\"grey-back\"\u003e\u003cstrong\u003eMolecular Weight:\u003c\/strong\u003e 3367.95 g\/mol\u003c\/p\u003e\n\u003cp class=\"white-back\"\u003e\u003cstrong\u003eMolecular Formula:\u003c\/strong\u003e C\u003csub\u003e152\u003c\/sub\u003eH\u003csub\u003e252\u003c\/sub\u003eN\u003csub\u003e44\u003c\/sub\u003eO\u003csub\u003e42\u003c\/sub\u003e\u003c\/p\u003e\n\u003cp class=\"grey-back\"\u003e\u003cstrong\u003eSequence:\u003c\/strong\u003e H-Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2\u003c\/p\u003e\n\u003cp style=\"margin-bottom: 30px;\" class=\"white-back\"\u003e\u003cstrong\u003eSynonyms:\u003c\/strong\u003e Mod GRF (1-29)\u003c\/p\u003e\n\u003ch3\u003eMod GRF (1-29) Research\u003c\/h3\u003e\n\u003cp class=\"white-back-d\"\u003e\u003cstrong\u003eModified GRF 1-29 and Somatotroph Cells\u003c\/strong\u003e\u003cbr\u003eModified GRF (1-29) is believed to stimulate the release of growth hormone by binding to specific receptors referred to as growth hormone-releasing hormone (GHRH) receptors on somatotroph cells in the anterior pituitary gland. These somatotroph cells are posited to be responsible for producing and secreting growth hormone. Research suggests that when Modified GRF (1-29) attaches to these receptors, it may cause the receptors to change in shape, which initiates a series of intracellular signaling events.\u003csup\u003e[3]\u003c\/sup\u003e For example, this receptor activation may lead to the stimulation of G-proteins located on the inner surface of the cell membrane. Activated G-proteins may then promote the production of secondary messenger molecules within the cell, such as cyclic adenosine monophosphate (cAMP) and inositol triphosphate (IP3).\u003cbr\u003e\u003cbr\u003eAn increase in cAMP levels may activate protein kinases—enzymes that add phosphate groups to specific target proteins. These phosphorylated proteins may include transcription factors that move into the cell nucleus and influence the transcription of genes involved in the synthesis and secretion of growth hormone. Consequently, somatotroph cells accumulate vesicles containing growth hormone molecules. As a result of these molecular events, the vesicles containing growth hormone may fuse with the cell membrane of the somatotroph cells, which allows the release of the hormone.\u003c\/p\u003e\n\u003cp class=\"grey-back-d\"\u003e\u003cstrong\u003eModified GRF 1-29 and Growth Hormone Synthesis\u003c\/strong\u003e\u003cbr\u003eScientific investigations have focused on partially modified versions of Mod GRF 1-29 and its potential magnitude of the influence on growth hormone synthesis. In one notable study, researchers observed a significant increase in growth hormone secretion by somatotroph cells within the anterior pituitary gland after exposure to the Mod GRF 1-29 analog. Specifically, there was an approximate 70% to 107% rise in the average amount of growth hormone released over 12 hours.\u003csup\u003e[4]\u003c\/sup\u003e This substantial support suggests that the modified peptides have a pronounced potential to stimulate growth hormone production.\u003cbr\u003e\u003cbr\u003eDespite these findings, it remains unclear whether the heightened levels of growth hormone are maintained over time or if they represent a transient spike. Additional research has provided data that Mod GRF 1-29 may elevate the total RNA content in the pituitary gland and increase the levels of growth hormone messenger RNA (mRNA).\u003csup\u003e[5]\u003c\/sup\u003e This suggests a possible proliferation of somatotroph cells. The researchers proposed that the peptide-induced an increase in both total pituitary RNA and growth hormone mRNA levels, implying that somatotroph cell numbers had expanded.\u003c\/p\u003e\n\u003cp class=\"white-back-d\"\u003e\u003cstrong\u003eModified GRF 1-29 and Anabolic Potential\u003c\/strong\u003e\u003cbr\u003eBy promoting potential growth hormone secretion, Mod GRF 1-29 may activate anabolic signaling pathways in experimental models. Studies have suggested that the exposure of research models to Mod GRF 1-29 in laboratory settings might lead to increased levels of insulin-like growth factor 1 (IGF-1), a critical mediator of growth hormone’s anabolic potential.\u003csup\u003e[4]\u003c\/sup\u003e IGF-1 is mainly produced in liver cells but is also synthesized in various other tissues under the influence of growth hormone. Research indicates that IGF-1 levels may rise by approximately 28% following administration of Mod GRF 1-29.\u003cbr\u003e\u003cbr\u003eThe elevation in IGF-1 is associated with increased thickness of dermal tissue, potentially due to the anabolic actions of growth hormone and IGF-1 on collagen-producing cells like fibroblasts. Additionally, some data supports scientists' observations of significant hypertrophy of muscular tissue in laboratory settings. Some of these trials resulted in an average gain of lean muscular tissue mass of about 2.77 lbs. These observations suggest that Mod GRF 1-29 may support anabolic processes in experimental settings.\u003c\/p\u003e\n\u003cp class=\"grey-back-d\"\u003e\u003cstrong\u003eModified GRF 1-29 and Cardiac Function\u003c\/strong\u003e\u003cbr\u003eResearch in rodent models has suggested that GHRH analogs similar to Mod GRF 1-29 may support the capacity of the heart to pump blood, even following events that are typically believed to contribute to cardiac dysfunction.\u003csup\u003e[6]\u003c\/sup\u003e More specifically, the researchers comment that \u003cem\u003e“Various studies [suggest] that GHRH agonists promote repair of cardiac tissue, producing improvement of ejection fraction and reduction of infarct size in rats, reduction of infarct scar in swine, and attenuation of cardiac hypertrophy in mice.” \u003c\/em\u003eThese positive actions are believed to occur through activation of the GHRH receptor. As such, these actions may be inhibited by substances that block this receptor.\u003cbr\u003e\u003cbr\u003eThe protective mechanisms may involve the stimulation of intracellular signaling pathways, including the adenylyl cyclase\/cyclic AMP\/protein kinase A (PKA) pathway, as well as the activation of MAPK ERK1\/2 and phosphatidylinositol 3-kinase\/Akt pathways. Additionally, GHRH analogs may counteract artificially induced increases in pro-apoptotic signaling within these cells. Research also suggests that GHRH analogs may oppose experimentally induced hypertrophy of cardiomyocytes, whether they are adult heart cells or derived from induced pluripotent stem cells. Specifically, analogs may inhibit the expression of genes associated with hypertrophy and modulate related signaling pathways. This includes supporting signaling through Gαs\/cAMP\/PKA and promoting the phosphorylation of phospholamban at the serine 16 position\/ Researchers believe this action may have anti-hypertrophic potential.\u003cbr\u003e\u003cbr\u003eImportantly, the anti-hypertrophic properties of GHRH analogs involve blocking the expression of the exchange protein directly activated by cAMP1 (Epac1) induced by phenylephrine. This protein plays a significant role in the development of hypertrophy. Despite these findings, along with other GHRH analogs, it is currently unclear whether Mod GRF 1-29 shares this cardioprotective and anti-hypertrophic potential.\u003c\/p\u003e\n\u003cp class=\"white-back-d\"\u003e\u003cstrong\u003eModified GRF 1-29 and Thyroid, Growth Hormone\u003c\/strong\u003e\u003cbr\u003eMalfunctioning of the thyroid gland is often associated with concomitant issues in growth hormone release. Research studies have suggested that research models of hyperthyroidism under the influence of thyroid replacement hormone may indicate stronger reactions to GRF, providing a possible link between thyroid hormone and growth hormone.\u003csup\u003e[7]\u003c\/sup\u003e The scientists commented the following: \u003cem\u003e“These data indicate that thyroid hormone […] enhances the responsiveness of the somatotroph to GRF 1-29.”\u003c\/em\u003e\u003c\/p\u003e\n\u003cp style=\"margin-bottom: 30px;\" class=\"grey-back-d\"\u003e\u003cstrong\u003eModified GRF 1-29 and the Intestine\u003c\/strong\u003e\u003cbr\u003eResearch in monkeys suggested that Modified GRF 1-29 may bind with receptors to potentially support bowel motility. Better-supported bowel movement is considered to be crucial in inflammatory bowel diseases. The peptide appears to interact with VIPC1, present on the smooth muscle of the reproductive, gastrointestinal, and urinary systems.\u003csup\u003e[8][9]\u003c\/sup\u003e These conditions may potentially trigger a great deal of morbidity.\u003c\/p\u003e\n\u003ch3 style=\"color: #555;\"\u003eReferences\u003c\/h3\u003e\n\u003cdiv style=\"margin-bottom: 30px;\" class=\"white-back-d\"\u003e\n\u003col style=\"color: #555;\"\u003e\n\u003cli\u003eCen, L. P., Ng, T. K., Chu, W. K., \u0026amp; Pang, C. P. (2022). Growth hormone-releasing hormone receptor signaling in experimental ocular inflammation and neuroprotection. Neural regeneration research, 17(12), 2643–2648.\u003c\/li\u003e\n\u003cli\u003eJetté, L., Léger, R., Thibaudeau, K., Benquet, C., Robitaille, M., Pellerin, I., Paradis, V., van Wyk, P., Pham, K., \u0026amp; Bridon, D. P. (2005). Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology, 146(7), 3052–3058.\u003c\/li\u003e\n\u003cli\u003eZhou, F., Zhang, H., Cong, Z., Zhao, L. H., Zhou, Q., Mao, C., Cheng, X., Shen, D. D., Cai, X., Ma, C., Wang, Y., Dai, A., Zhou, Y., Sun, W., Zhao, F., Zhao, S., Jiang, H., Jiang, Y., Yang, D., Eric Xu, H., … Wang, M. W. (2020). Structural basis for activation of the growth hormone-releasing hormone receptor. Nature communications, 11(1), 5205.\u003c\/li\u003e\n\u003cli\u003eKhorram, O., Laughlin, G. A., \u0026amp; Yen, S. S. (1997). Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women. The Journal of clinical endocrinology and metabolism, 82(5), 1472–1479.\u003c\/li\u003e\n\u003cli\u003eAlba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, Salvatori R. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006 Dec;291(6):E1290-4. . Epub 2006 Jul 5. PMID: 16822960.\u003c\/li\u003e\n\u003cli\u003eSchally, A. V., Zhang, X., Cai, R., Hare, J. M., Granata, R., \u0026amp; Bartoli, M. (2019). Actions and Potential Therapeutic Applications of Growth Hormone-Releasing Hormone Agonists. Endocrinology, 160(7), 1600–1612.\u003c\/li\u003e\n\u003cli\u003eValcavi, R., Jordan, V., Dieguez, C., John, R., Manicardi, E., Portioli, I., Rodriguez-Arnao, M. D., Gomez-Pan, A., Hall, R., \u0026amp; Scanlon, M. F. (1986). Growth hormone responses to GRF 1-29 in patients with primary hypothyroidism before and during replacement therapy with thyroxine. Clinical endocrinology, 24(6), 693–698.\u003c\/li\u003e\n\u003cli\u003eIto, T., Igarashi, H., Pradhan, T. K., Hou, W., Mantey, S. A., Taylor, J. E., Murphy, W. A., Coy, D. H., \u0026amp; Jensen, R. T. (2001). GI side-effects of a possible therapeutic GRF analog in monkeys are likely due to VIP receptor agonist activity. Peptides, 22(7), 1139–1151.\u003c\/li\u003e\n\u003cli\u003eWaelbroeck, M., Robberecht, P., Coy, D. H., Camus, J. C., De Neef, P., \u0026amp; Christophe, J. (1985). Interaction of growth hormone-releasing factor (GRF) and 14 GRF analogs with vasoactive intestinal peptide (VIP) receptors of rat pancreas. Discovery of (N-Ac-Tyr1,D-Phe2)-GRF(1-29)-NH2 as a VIP antagonist. Endocrinology, 116(6), 2643–2649. \u003ca rel=\"noopener\" href=\"https:\/\/doi.org\/10.1210\/endo-116-6-2643\" target=\"_blank\"\u003ehttps:\/\/doi.org\/10.1210\/endo-116-6-2643\u003c\/a\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"author-details\"\u003e\n\u003ch2\u003e\u003ca href=\"https:\/\/biotechpeptides.com\/dr-marinov\/\"\u003eDr. Usman\u003c\/a\u003e\u003c\/h2\u003e\n\u003cp\u003eDr. Usman (BSc, MBBS, MaRCP) completed his studies in medicine at the Royal College of Physicians, London. He is an avid researcher with more than 30 publications in internationally recognized peer-reviewed journals. Dr. Usman has worked as a researcher and a medical consultant for reputable pharmaceutical companies such as Johnson \u0026amp; Johnson and Sanofi.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"mysite","offers":[{"title":"Default Title","offer_id":51786428776765,"sku":"sku2194756141379","price":150.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0997\/4474\/3741\/files\/Mod-GRF-5MG-1.webp?v=1780466146"},{"product_id":"ll-37-5mg","title":"(💪Antibacterial) LL-37 (5mg) - 10 Vials","description":"\u003cdiv class=\"et_pb_tab_content\"\u003e\n\u003cdiv class=\"pro-description-con\"\u003e\n\u003cp\u003e🧬 What is LL-37?\u003c\/p\u003e\n\u003cp\u003eLL-37 is a peptide naturally produced by the human body, primarily by:\u003c\/p\u003e\n\u003cp\u003eSkin cells\u003cbr\u003eNeutrophils (white blood cells)\u003cbr\u003eEpithelial tissue\u003c\/p\u003e\n\u003cp\u003eIts core functions are:\u003cbr\u003e🛡️ Antimicrobial + Immune Modulation + Tissue Repair\u003c\/p\u003e\n\u003cp\u003e🔥 Primary Biological Effects\u003cbr\u003e🦠 1️⃣ Antibacterial (Core Function)\u003c\/p\u003e\n\u003cp\u003eLL-37 can directly eliminate:\u003c\/p\u003e\n\u003cp\u003eBacteria 🦠\u003cbr\u003eViruses 🧬\u003cbr\u003eFungi 🍄\u003c\/p\u003e\n\u003cp\u003eBy:\u003cbr\u003e➡️ Destroying the cell membranes of pathogens\u003c\/p\u003e\n\u003cp\u003eIt is classified as a “broad-spectrum natural antibiotic.”\u003c\/p\u003e\n\u003cp\u003e🧠 2️⃣ Immune Modulation\u003c\/p\u003e\n\u003cp\u003eLL-37 does more than just “kill pathogens”; it also modulates the immune system:\u003c\/p\u003e\n\u003cp\u003eRegulates inflammatory responses\u003cbr\u003eAttracts immune cells\u003cbr\u003eControls immune balance\u003c\/p\u003e\n\u003cp\u003eTherefore, it can:\u003cbr\u003e🔥 Act as an anti-inflammatory, or in certain cases, promote inflammatory responses (bidirectional regulation)\u003c\/p\u003e\n\u003cp\u003e🩹 3️⃣ Wound Healing\u003c\/p\u003e\n\u003cp\u003eLL-37 is being studied for:\u003c\/p\u003e\n\u003cp\u003ePromoting skin repair\u003cbr\u003eAccelerating wound healing\u003cbr\u003eStimulating tissue regeneration\u003cbr\u003ePromoting angiogenesis\u003cbr\u003e🧴 Potential in Medicine\/Research\u003c\/p\u003e\n\u003cp\u003eResearch areas include:\u003c\/p\u003e\n\u003cp\u003eChronic wounds (diabetic foot)\u003cbr\u003eSkin infections\u003cbr\u003eEczema \/ Psoriasis\u003cbr\u003eAntibacterial alternatives to antibiotics\u003cbr\u003eRegulation of immune disorders\u003c\/p\u003e\n\u003ch3\u003e\u003cbr\u003e\u003c\/h3\u003e\n\u003ch3\u003eLL-37 Peptide\u003c\/h3\u003e\n\u003cp class=\"white-back-d\" style=\"margin-bottom: 30px;\"\u003eLL-37 is a Cathelicidin, a protein family of unique and diverse functions. These peptides, produced by macrophages and polymorphonuclear leukocytes (both types of white blood cells), have been suggested to exhibit bactericidal action. The entire group is classified as antimicrobial peptides (AMPs). The peptide, in particular, has been researched in relation to autoimmune disease, cancer, and wound recovery.\u003csup\u003e[1]\u003c\/sup\u003e For example, researchers note that \u003cem\u003e“Corneal and conjunctival epithelia express LL-37 as part of mucosal innate immunity to protect against bacterial and viral ocular infections.”\u003c\/em\u003e\u003c\/p\u003e\n\u003ch3\u003eSpecifications\u003c\/h3\u003e\n\u003cp class=\"grey-back\"\u003e\u003cstrong\u003eOther Known Titles:\u003c\/strong\u003e CAP-18\u003c\/p\u003e\n\u003cp class=\"white-back\"\u003e\u003cstrong\u003eMolecular Formula:\u003c\/strong\u003e C\u003csub\u003e205\u003c\/sub\u003eH\u003csub\u003e340\u003c\/sub\u003eN\u003csub\u003e50\u003c\/sub\u003eO\u003csub\u003e53\u003c\/sub\u003e\u003c\/p\u003e\n\u003cp class=\"grey-back\"\u003e\u003cstrong\u003eMolecular Weight:\u003c\/strong\u003e 4493.34 g\/mol\u003c\/p\u003e\n\u003cp class=\"white-back\" style=\"margin-bottom: 30px;\"\u003e\u003cstrong\u003eSequence:\u003c\/strong\u003e Leu-Leu-Gly-Asp-Phe-Phe-Arg-Lys-Ser-Lys-GluLys-Ile-Gly-Lys-Glu-Phe-Lys-Arg-Ile-Val-Gln-Arg-Ile-Lys-Asp-Phe-Leu-Arg-Asn-Leu-Val-Pro-ArgThr-Glu-Ser\u003c\/p\u003e\n\u003ch3\u003eLL-37 Peptide Research\u003c\/h3\u003e\n\u003cp class=\"grey-back-d\"\u003e\u003cstrong\u003eLL-37 and Inflammatory Disease Models\u003c\/strong\u003e\u003cbr\u003eLL-37, although essentially researched as an antimicrobial peptide, has also been examined in research related to different inflammatory diseases such as lupus, rheumatoid arthritis, psoriasis, and atherosclerosis. LL-37 researchers suggest the peptide’s diverse immune system modulating behaviors based on the type of cells involved and the local inflammatory environment. It has been suggested to reduce apoptotic death of keratinocytes, improve IFN-alpha synthesis, suppress signaling through toll-like receptor 4 (TLR4), modify chemotaxis of neutrophils and eosinophils,\u003csup\u003e[2] \u003c\/sup\u003etrigger IL-18 production, and potentially reduce levels of atherosclerotic plaques. Interestingly, LL-37 (aka CAP-18) appears to stimulate the immune system in a different manner depending on the trigger. Cell culture studies have observed the importance of the inflammatory environment in determining the immune response to LL-37. T-cells appear to improve inflammatory action via LL-37 when not activated but minimize the inflammatory action when activated.\u003cbr\u003e\u003cbr\u003eThe peptide appears to mediate homeostasis of immunological response, thus controlling it from being hyperactive in instances of infection. There appears to be a strong correlation between the peptide levels and the extent of the disease. Initially, CAP-18 was thought to promote autoimmune disorders, but recent results have suggested it may help to abate the damage.\u003csup\u003e[3]\u003c\/sup\u003e The researchers outline that the peptide has a role \u003cem\u003e“in the modulation of immune and inflammatory pathways and their effects on autoimmune and inflammatory diseases.”\u003c\/em\u003e High levels of the peptide may thus help check further increased inflammation.\u003c\/p\u003e\n\u003cp class=\"white-back-d\"\u003e\u003cstrong\u003eLL-37 and Antimicrobial Characteristics\u003c\/strong\u003e\u003cbr\u003eLL-37 appears to be an important biomolecule of innate immunity and one of the initial proteins to activate during infection. Research findings in skin infection studies suggest that the peptide, though present in limited skin cells, appears to accumulate very fast when invading pathogens are present.\u003csup\u003e[4]\u003c\/sup\u003e It may work with other proteins, like beta-defensin 2, to fight infection. The peptide appears to bind to bacterial lipopolysaccharide (LPS) of the outer membrane of gram-negative bacteria. LPS is considered critical for the membrane integrity of these bacteria. The possible action of LL-37 to bind to and interfere with LPS may make it toxic for certain bacteria. LL-37 may act against gram-positive pathogens, as research on staph infections and other serious bacteria suggested. Research indicates that LL-37 \/ CAP-18 may improve lysozyme’s action, which destroys gram-positive bacteria like\u003cem\u003e Staph aureus.\u003c\/em\u003e\u003cbr\u003e\u003cbr\u003eLL-37 may also be heightened and exert antimicrobial actions against nearby potential threats in models of gastrointestinal ulcers, as they report increased peptide expression.\u003csup\u003e[5]\u003c\/sup\u003e This heightened production of LL-37 is likely influenced by the activation of Toll-like receptor 3 (TLR-3). TLR-3 is a type of receptor involved in the immune response, which may be activated by its specific ligand, polyinosinic-polycytidylic acid (poly(I)), a synthetic analog of double-stranded RNA. The interaction with poly(I) may trigger a series of intracellular signaling events that include the involvement of proteins such as Toll\/IL-1 receptor (TIR) domain-containing adaptor-inducing interferon (TRIF), tumor necrosis factor receptor-associated factor 6 (TRAF6), and transforming growth factor β-activated kinase 1 (TAK1). These proteins appear to play crucial roles in immune signaling pathways that might lead to the enhanced expression of LL-37. The peptide's role in the gastrointestinal tract extends to possibly mitigating microbial damage to the gastrointestinal (GI) mucosa via the interactions of the peptide with LPS. Furthermore, the presence of LL-37 may help reduce the secretion of pro-inflammatory cytokines such as interleukin-6 (IL-6) and IL-8, which are significant in the inflammatory response. This reduction is potentially observed in colonic subepithelial myofibroblasts (SEMFs), cells that are part of the connective tissue and may play a role in wound recovery and fibrosis. By moderating the inflammatory response through these interactions, LL-37 might contribute to safeguarding the integrity of the GI tract lining.\u003c\/p\u003e\n\u003cp class=\"grey-back-d\"\u003e\u003cstrong\u003eLL-37 and Lung Disease Models\u003c\/strong\u003e\u003cbr\u003eLPS is found in several different organisms and, in some instances, may become airborne when an environment is contaminated by mold or other fungi. Normal lung tissue responds by producing mucus upon LPS inhalation. Unfortunately, the response is often insufficient to intercept toxic dust syndrome and respiratory diseases like asthma and COPD. LL-37 has been studied in research on toxic dust syndrome.\u003csup\u003e[6]\u003c\/sup\u003e LL-37 appears to promote the proliferation of epithelial cells and the closure of wounds in lung diseases. The peptide may attract airway epithelial cells to injury sites and help vascularization, wound recovery, and supply of nutrition to the newly formed tissue.\u003c\/p\u003e\n\u003cp class=\"white-back-d\"\u003e\u003cstrong\u003eLL-37 Peptide and Arthritis Models\u003c\/strong\u003e\u003cbr\u003eResearch in murine models observed high LL-37 levels in the joints of rat models of rheumatoid arthritis. Whether the peptide exerts positive or negative actions in such models is unknown. However, several findings indicate the potential of the peptide in inflammation. LL-37 deficiency does not appear to change the outcomes in animal models of arthritis or lupus.\u003csup\u003e[7]\u003c\/sup\u003e Animals expressing the peptide may show the same disease outcome as those lacking the peptide. These results indicate that the physiological reactions in enhanced levels of cathelicidins in arthritis are incidental.\u003cbr\u003e\u003cbr\u003ePeptides derived from LL-37 may reduce collagen damage, which occurs in inflammatory arthritis. Direct exposure of these peptides to arthritic joints in rats was observed to reduce both the severity of the disease and serum levels of antibodies against type II collagen. Direct interleukin-32 (IL-32) involvement in the severity of inflammatory arthritis has been reported. LL-37 and its derivatives may be able to regulate the level of IL-32 response. Researchers consider it reasonable to speculate that the peptide is protective in this disease scenario. Synovial fluid fibroblasts increase toll-like receptor 3 levels, which scientists consider worsens the arthritic condition by increasing inflammatory cytokine expression. LL-37 may interact with TLR4 and either promote pro-inflammatory or anti-inflammatory outcomes.\u003csup\u003e[8]\u003c\/sup\u003e It is yet to be confirmed if LL-37 \/ CAP-18 mediates the same actions against the backdrop of increased TLR3. The peptide has been examined in experimental studies to selectively decrease pro-inflammatory macrophage responses, and researchers suggest its regulation of inflammation to be selective.\u003c\/p\u003e\n\u003cp class=\"grey-back-d\"\u003e\u003cstrong\u003eLL-37 and Intestinal Cancer\u003c\/strong\u003e\u003cbr\u003eCell culture-based research studies have suggested potential multifaceted functions of the peptide in the intestine. The peptide appears to improve the migration of cells necessary for epithelial barrier maintenance of the intestine. LL-37 may reduce apoptosis when there is intestinal inflammation, helping to reduce inflammation's causes and associated pathogenesis. Studies suggest LL-37 pairs with beta-defensin 2 to help in wound recovery. Research indicates that the peptides may work simultaneously to repair and maintain the intestinal epithelium while decreasing TNF-related cell death.\u003csup\u003e[9]\u003c\/sup\u003e Despite being the principal compounds researched in inflammatory bowel conditions, TNF-alpha inhibitors have been reported to exhibit adverse ancillary impacts. LL-37-exposure may potentially reduce the dependence on TNF-alpha inhibitors. Research in the peptide action on cancer cells has generated mixed reports.\u003c\/p\u003e\n\u003cp class=\"white-back-d\"\u003e\u003cstrong\u003eLL-37 and Blood Vessel Growth\u003c\/strong\u003e\u003cbr\u003eThe peptide appears to produce prostaglandin E2 (PGE2) in endothelial cells, which are cells that line the interior surface of blood vessels.\u003csup\u003e[10]\u003c\/sup\u003e In endothelial cells, PGE2 promotes the development of blood vessels via a process called angiogenesis. It is considered crucial to regulate angiogenesis as it impacts cancer development, stroke outcomes, heart disease, and wound recovery, among others. LL-37 helps to study angiogenesis in-depth to promote it in cardiac disease and discourage cancer milieu. Further research suggests that the peptide appears to support several critical functions of endothelial cells.\u003csup\u003e[11]\u003c\/sup\u003e These functions include cell proliferation, which is the process of cells multiplying; cell migration, which involves the movement of cells from one location to another; and the creation of tube-like structures that resemble small capillaries. Research conducted on mouse models with induced catabolism—where the mouse body breaks down molecules for energy—employed synthetic and natural recombinant versions of LL-37. This research tentatively indicates that exposure to LL-37 may promote the development of new blood vessels and the recovery of epithelial tissues, which include skin and organ linings. Such preliminary findings tentatively support the theory that LL-37 may play a vital role in enhancing wound recovery by possibly influencing the new blood vessel formation process, known as \u003cem\u003evascularization\u003c\/em\u003e.\u003c\/p\u003e\n\u003cp class=\"grey-back-d\" style=\"margin-bottom: 30px;\"\u003e\u003cstrong\u003eLL-37 and Immune Cells\u003c\/strong\u003e\u003cbr\u003eStudies suggest that LL-37 may potentially enhance the immune system's ability to respond to cellular damage.\u003csup\u003e[12]\u003c\/sup\u003e This enhancement might occur through the modulation of the immune system's recognition mechanisms for self-nucleic acids, which include DNA and RNA. It is speculated that this modulation occurs when LL-37 interacts with particular types of cellular receptors, notably scavenger receptors (SRs). These receptors are deemed key in a process known as \u003cem\u003eclathrin-dependent endocytosis\u003c\/em\u003e, which is believed to be crucial for activating inflammatory pathways in cells. In addition, the peptide LL-37 is thought to facilitate the association of double-stranded RNA (dsRNA) with scavenger receptors. This interaction might initiate a cascade of signaling events that ultimately lead to the expression of cytokines, important signaling molecules in the immune response. The study further suggests that the specific interaction between LL-37 and certain scavenger receptors, such as SR-A6 and SR-B1, may be vital. The research also explores the idea that LL-37 might influence the immune system by potentially altering the function of intracellular signaling pathways. These pathways include Toll-like receptors (TLRs) and interferon regulatory factors (IRFs), which are commonly activated in response to foreign nucleic acids. The study posits that through clathrin-mediated endocytosis, LL-37 may facilitate the entry of immune-modulating molecules into cells, an essential step for initiating an immune response. This suggests a sophisticated mechanism by which LL-37 might regulate immune reactions at a cellular level.\u003c\/p\u003e\n\u003ch3 style=\"color: #555;\"\u003eReferences\u003c\/h3\u003e\n\u003cdiv class=\"white-back-d\" style=\"padding-bottom: 5px !important; margin-bottom: 25px !important;\"\u003e\n\u003col style=\"color: #555;\"\u003e\n\u003cli\u003eGordon YJ, Huang LC, Romanowski EG, Yates KA, Proske RJ, McDermott AM. Human cathelicidin (LL-37), a multifunctional peptide, is expressed by ocular surface epithelia and has potent antibacterial and antiviral activity. Curr Eye Res. 2005 May;30(5):385-94. . PMID: 16020269; PMCID: PMC1497871.\u003c\/li\u003e\n\u003cli\u003eAlalwani SM, Sierigk J, Herr C, Pinkenburg O, Gallo R, Vogelmeier C, Bals R. The antimicrobial peptide LL-37 modulates the inflammatory and host defense response of human neutrophils. Eur J Immunol. 2010 Apr;40(4):1118-26. . PMID: 20140902; PMCID: PMC2908514.\u003c\/li\u003e\n\u003cli\u003eKahlenberg JM, Kaplan MJ. Little peptide, big effects: the role of LL-37 in inflammation and autoimmune disease. J Immunol. 2013 Nov 15;191(10):4895-901. . PMID: 24185823; PMCID: PMC3836506.\u003c\/li\u003e\n\u003cli\u003eReinholz M, Ruzicka T, Schauber J. Cathelicidin LL-37: an antimicrobial peptide with a role in inflammatory skin disease. Ann Dermatol. 2012 May;24(2):126-35. . Epub 2012 Apr 26. PMID: 22577261; PMCID: PMC3346901.\u003c\/li\u003e\n\u003cli\u003eKusaka; et al. Expression of human cathelicidin peptide LL-37 in inflammatory bowel disease. Clin Exp Immunol. 2018 Jan;19(11). Epub 2017 Sep 28.\u003c\/li\u003e\n\u003cli\u003eGolec M. Cathelicidin LL-37: LPS-neutralizing, pleiotropic peptide. Ann Agric Environ Med. 2007;14(1):1-4. PMID: 17655171.\u003c\/li\u003e\n\u003cli\u003eMoreno-Angarita A, Aragón CC, Tobón GJ. Cathelicidin LL-37: A new important molecule in the pathophysiology of systemic lupus erythematosus. J Transl Autoimmun. 2019 Dec 17;3:100029. . PMID: 32743514; PMCID: PMC7388365.\u003c\/li\u003e\n\u003cli\u003eSingh D, Vaughan R, Kao CC. LL-37 peptide enhancement of signal transduction by Toll-like receptor 3 is regulated by pH: identification of a peptide antagonist of LL-37. J Biol Chem. 2014 Oct 3;289(40):27614-24. . Epub 2014 Aug 4. PMID: 25092290; PMCID: PMC4183800.\u003c\/li\u003e\n\u003cli\u003ePiktel E, Niemirowicz K, Wnorowska U, Wątek M, Wollny T, Głuszek K, Góźdź S, Levental I, Bucki R. The Role of Cathelicidin LL-37 in Cancer Development. Arch Immunol Ther Exp (Warsz). 2016 Feb;64(1):33-46. . Epub 2015 Sep 22. PMID: 26395996; PMCID: PMC4713713.\u003c\/li\u003e\n\u003cli\u003eSalvado MD, Di Gennaro A, Lindbom L, Agerberth B, Haeggström JZ. Cathelicidin LL-37 induces angiogenesis via PGE2-EP3 signaling in endothelial cells, in vivo inhibition by aspirin. Arterioscler Thromb Vasc Biol. 2013 Aug;33(8):1965-72. doi: 10.1161\/ATVBAHA.113.301851. Epub 2013 Jun 13. PMID: 23766266.\u003c\/li\u003e\n\u003cli\u003eRamos R, Silva JP, Rodrigues AC, Costa R, Guardão L, Schmitt F, Soares R, Vilanova M, Domingues L, Gama M. Wound healing activity of the human antimicrobial peptide LL37. Peptides. 2011 Jul;32(7):1469-76. doi: 10.1016\/j.peptides.2011.06.005. Epub 2011 Jun 13.\u003c\/li\u003e\n\u003cli\u003eTakahashi, T., Kulkarni, N.N., Lee, E.Y. et al. Cathelicidin promotes inflammation by enabling binding of self-RNA to cell surface scavenger receptors. Sci Rep 8, 4032 (2018).\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"author-details\"\u003e\n\u003ch2\u003e\u003ca href=\"https:\/\/biotechpeptides.com\/dr-marinov\/\"\u003eDr. Usman\u003c\/a\u003e\u003c\/h2\u003e\n\u003cp\u003eDr. Usman (BSc, MBBS, MaRCP) completed his studies in medicine at the Royal College of Physicians, London. He is an avid researcher with more than 30 publications in internationally recognized peer-reviewed journals. Dr. Usman has worked as a researcher and a medical consultant for reputable pharmaceutical companies such as Johnson \u0026amp; Johnson and Sanofi.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"mysite","offers":[{"title":"Default Title","offer_id":51786429071677,"sku":"sku2194756138911","price":300.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0997\/4474\/3741\/files\/LL_37-5MG-1.webp?v=1780466155"},{"product_id":"adipotide-ftpp-10mg","title":"(🔥Fat loss) Adipotide FTPP 10mg-10 Vials","description":"\u003cdiv class=\"et_pb_tab_content\"\u003e\n\u003cdiv class=\"pro-description-con\"\u003e\n\u003cp\u003e🧬 What is Adipotide \/ FTPP?\u003c\/p\u003e\n\u003cp\u003eAdipotide (also known as FTPP) is designed to:\u003c\/p\u003e\n\u003cp\u003eTarget blood vessels in adipose tissue\u003cbr\u003eDisrupt the environment necessary for fat cells to survive\u003cbr\u003eInduce apoptosis (cell death) in fat cells\u003c\/p\u003e\n\u003cp\u003eIts mechanism of action is unique; it does not rely on traditional “fat burning,” but rather:\u003c\/p\u003e\n\u003cp\u003e👉 “Fat loss by cutting off blood supply”\u003c\/p\u003e\n\u003cp\u003e🔥 Mechanism of Action (Key Points)\u003cbr\u003e🧪 1️⃣ Targets Fat Vessels\u003c\/p\u003e\n\u003cp\u003eAdipotide binds to specific receptors on the surface of adipose tissue:\u003c\/p\u003e\n\u003cp\u003e➡️ It targets only the vascular system of adipose tissue\u003cbr\u003e➡️ It does not directly “burn fat,” but rather causes fat cells to become oxygen-deprived\u003c\/p\u003e\n\u003ch3\u003e\n\u003cbr\u003eAdipotide FTPP Peptide\u003c\/h3\u003e\n\u003cp class=\"white-back-d\" style=\"margin-bottom: 30px;\"\u003eAdipotide FTPP is a category of proapoptotic peptides intended to eliminate fat cells.\u003csup\u003e[1]\u003c\/sup\u003e They appear to cut off the blood supply specifically to the adipose tissues and not the vessels supplying blood to the rest of the organism. Reports of studies performed in monkeys have suggested their potential to induce weight loss, which may improve symptoms of insulin resistance and reduces the symptoms of type 2 diabetes.\u003c\/p\u003e\n\u003ch3\u003eSpecifications\u003c\/h3\u003e\n\u003cp class=\"grey-back\"\u003e\u003cstrong\u003eOther Known Titles:\u003c\/strong\u003e Adipotide\u003c\/p\u003e\n\u003cp class=\"white-back\"\u003e\u003cstrong\u003eMolecular Formula:\u003c\/strong\u003e C\u003csub\u003e152\u003c\/sub\u003eH\u003csub\u003e252\u003c\/sub\u003eN\u003csub\u003e44\u003c\/sub\u003eO\u003csub\u003e42\u003c\/sub\u003e\u003c\/p\u003e\n\u003cp class=\"grey-back\"\u003e\u003cstrong\u003eMolecular Weight:\u003c\/strong\u003e 2611.41 g\/mol\u003c\/p\u003e\n\u003cp class=\"white-back\" style=\"margin-bottom: 30px;\"\u003e\u003cstrong\u003eSequence:\u003c\/strong\u003e Cys-Lys-Gly-Gly-Arg-Ala-Lys-Asp-Cys—Gly-Gly--(Lys-Leu-Ala-Lys-Leu-Ala-Lys)2\u003c\/p\u003e\n\u003ch3\u003eAdipotide FTPP Research\u003c\/h3\u003e\n\u003cp class=\"grey-back-d\"\u003e\u003cstrong\u003eAdipotide FTPP Mechanism of Action\u003c\/strong\u003e\u003cbr\u003eAdipotide has been suggested to exert action by binding to the receptors for two specific proteins, ANXA2 (Annexin A2) and prohibitin (PHB). It appears that these receptors may be expressed in a wide range of cells, but immunohistochemical analysis hypothesizes that they potentially form a unique ANXA2-prohibitin receptor system that are apparently found in white fat tissue.\u003csup\u003e[2] \u003c\/sup\u003eIt appears that these receptors were found on the endothelial cells of blood vessels that support white fat cells. Furthermore, research suggests that these receptors may play a role in regulating fatty acid transport in white adipose tissues (WAT).\u003csup\u003e[3]\u003c\/sup\u003e To potentially explore this notion, the researchers disrupted the binding between ANXA2 and prohibitin genetically or by utilizing a blocking peptide. Their findings seem to indicate that the efficiency of fatty acid transport might depend on the interaction between ANXA2 and prohibitin. Moreover, the study suggests that the interaction between ANXA2 and prohibitin may facilitate the transport of fatty acids from the endothelium into adipocytes. The researchers also stumbled upon the revelation that ANXA2 and prohibitin form a complex alongside the fatty acid transporter CD36.\u003cbr\u003e\u003cbr\u003eThis intricate connection involving ANXA2, prohibitin, and CD36 potentially plays a role in mediating fatty acid transport in white adipose tissues. Furthermore, the researchers noticed that the coexistence of prohibitin and CD36 on the surface of adipocytes appears to be induced by extracellular fatty acids. This lead them to the hypothesis that the presence of fatty acids in the external environment may trigger the interaction between prohibitin and CD36 on the adipocyte surface. Hypothetically, inhibiting the ANXA2 protein may lead to hypertrophy of white adipose cells due to reduced uptake of fatty acids. On the other hand, prohibitin is a multifunctional membrane-associated protein that may be thought to regulate cell survival and growth. By shuttling from the cell's membrane to its nucleus, it may hypothetically trigger apoptosis. Thus, the scientists commented that \u003cem\u003e“suggest that an unrecognized biochemical interaction between ANX2 and PHB regulates CD36-mediated fatty acid transport in WAT, thus revealing a new potential pathway for intervention in metabolic diseases.”\u003c\/em\u003e\u003c\/p\u003e\n\u003cp class=\"white-back-d\"\u003e\u003cstrong\u003eAdipotide FTPP Structure\u003c\/strong\u003e\u003cbr\u003eAdipotide appears to have a unique structure consisting of the amino acid sequence GKGGRAKDC-GG-D(KLAKLAK)2. The nine amino acid sequence CKGGRAKDC may exhibit a specific affinity to the ANXA2-prohibitin receptor system found in the blood vessels supporting white adipose cells.\u003csup\u003e[4]\u003c\/sup\u003e The researchers utilized phage display, a technique that is considered to enable the identification of specific peptide motifs, to isolate a peptide sequence CKGGRAKDC. Moreover, the CKGGRAKDC peptide appears to associate with a membrane protein called prohibitin, which has been identified as a potential vascular marker of adipose tissue. By directing a proapoptotic peptide towards prohibitin in the adipose vasculature, the researchers induced the ablation (removal) of white fat. This resulted in the possible resorption of established white adipose tissue and the potential normalization of metabolism. As a consequence, rapid obesity reversal was reported to be achieved. It is suggested that prohibitin is expressed in the blood vessels of white fat. However, it is crucial to note that the study solely focuses on elucidating the mechanisms involved and did not provide any definitive suggestions or implications regarding its potential.\u003cbr\u003e\u003cbr\u003eAt the same time, (KLAKLAK)2 may disrupt mitochondrial membranes upon receptor-mediated cell internalization and possibly cause programmed cell death. As Adipotide may bind to prohibitin in white adipose vasculature, it potentially triggers apoptosis and hypothetically results in the ablation of white fat cells. According to research, Adipotide and other similar peptidomimetics may hold potential for reducing both subcutaneous and visceral fat and may even target intra-organ fat, such as in fatty liver.\u003csup\u003e[5]\u003c\/sup\u003e In fact, the researchers posit that \u003cem\u003e“vascular-targeted nanotherapy has the potential to contribute to the control of adipose function and ectopic fat deposition associated with obesity and the metabolic syndrome.”\u003c\/em\u003e\u003c\/p\u003e\n\u003cp class=\"grey-back-d\"\u003e\u003cstrong\u003eAdipotide FTPP and Cancer Cells\u003c\/strong\u003e\u003cbr\u003eCancerous tissues can grow rapidly and become metastatic due to the large network of blood vessels. Suppose prohibitin, found in several cancer types, is targeted. In that case, it may be possible to mitigate cancer in a more focused manner and avoid the associated negative impacts brought about due to damage to surrounding tissues in certain chemotherapy scenarios. Some researchers posit that there may be a potential association between excess fat tissue cells and the occurrence of cancer cells. One study discussed several potential mechanisms that may help explain the potential association between obesity and the occurrence of aggressive prostate cancer cells (PCa), aka tumorigenesis.\u003csup\u003e[6]\u003c\/sup\u003e Three main mechanisms are highlighted: the insulin\/insulin-like growth factor (IGF)-1 axis, sex hormones, and adipokine signaling. The insulin\/IGF-1 axis appears implicated in the potential tumorigenesis associated with obesity, including PCa. It is suggested that high insulin levels resulting from a hyperinsulinemic state induced by diet may potentially accelerate tumor cell growth in PCa models.\u003cbr\u003e\u003cbr\u003eThe presence of the insulin receptor in PCa indicates a potential for insulin to stimulate its growth. Studies have associated higher serum C-peptide concentrations, serving as a surrogate for insulin levels, with an increase in PCa-specific mortality. Thus, it is hypothesized that insulin likely plays a key role in potentially explaining the connection between obesity and aggressive PCa. Obesity and hyperinsulinemia also potentially result in increased levels of bioactive IGF-1, a growth factor implicated in various cancers. Elevated circulating IGF-1 has been associated with an increased incidence of PCa, particularly in detectable cases. The upregulation of the IGF-1 receptor accompanies the transition of androgen-dependent PCa cell lines to androgen independence, and studies have suggested that IGF-1 potentially promotes PCa progression. Therefore, it is posited that IGF-1 may be associated with aggressive PCa, although its association with less aggressive, PSA-detected tumors remains uncertain. Testosterone (T) is potentially aromatized to estradiol (E) within adipocytes and prostate cells.\u003cbr\u003e\u003cbr\u003eObesity, characterized by increased adipose tissue mass and upregulation of the aromatization pathway, leads to potentially elevated serum and intracellular E levels. Although epidemiologic data does not consistently support a clear association between serum E and PCa risk, preclinical studies suggest that E may potentially promote PCa development and progression. Obesity is considered a state of chronic subclinical inflammation influenced by altered levels of adipokines. Leptin, potentially elevated in obesity, appears to exert pro-tumor impacts in PCa cell lines, inducing proliferation, inhibiting apoptosis, and increasing migration. However, epidemiologic studies do not consistently report a clear positive association between leptin and PCa risk or fatal PCa. On the other hand, adiponectin, which is considered to be reduced in obesity, predominantly exhibits anti-tumor effects. Reduced levels of adiponectin have potentially been associated with metastatic and fatal PCa. While the role of leptin in the link between obesity and aggressive PCa remains unclear, adiponectin appears to be associated with advanced aggressive PCa, reflecting the overall connection between obesity and PCa.\u003cbr\u003e\u003cbr\u003eObesity is also potentially associated with elevated serum interleukin (IL)-6 levels, primarily originating from adipose tissue. PCa cells and primary PCas potentially produce IL-6 and express IL-6 receptors, enabling them to respond to this proinflammatory adipokine.\u003c\/p\u003e\n\u003cp class=\"white-back-d\"\u003e\u003cstrong\u003eAdipotide and Glucose Tolerance\u003c\/strong\u003e\u003cbr\u003eGlucose tolerance, a common parameter in characterizing diabetes, is studied by performing a blood test and confirmed by testing fasting glucose levels. In another method, a specific amount of glucose is consumed, and then blood sugar levels are estimated. Metabolic syndromes such as diabetes have traditionally been controlled by nutritional intake and physical activity. Both require immense patience and dedication as the outcomes can take months, if not years, to exhibit significant improvement. Research with Adipotides has noted rapid weight-independent improvement in glucose tolerance in animal research models.\u003csup\u003e[7]\u003c\/sup\u003e This highlights the observation that reducing white fat by adipotide FTPP may simultaneously reduce glucose tolerance irrespective of the model’s weight. Although it is unclear whether Adipotide FTPP peptide may directly induce fat loss or whether it may decrease the appetite (an indirect factor), the former is more likely as changes in fat cell density and improved glucose tolerance have been observed even without associated weight loss.\u003c\/p\u003e\n\u003cp class=\"grey-back-d\" style=\"margin-bottom: 30px;\"\u003e\u003cstrong\u003eAdipotide And Fat Loss\u003c\/strong\u003e\u003cbr\u003eResearch on rhesus monkeys suggested the potential of this novel peptide to induce apoptosis, specifically in the vessels supplying blood to the white adipose tissues.\u003csup\u003e[8]\u003c\/sup\u003e The result being no blood cells and hence, the ensuing death of these fat cells. The eventual outcomes reported were rapid weight loss, decreased body mass index, and improved insulin sensitivity. Such changes were attributed in part to the potential of Adipotide FTPP to change the eating pattern of the monkeys, as the monkeys who exhibit a positive weight loss also exhibited a reduced appetite. Research has suggested that Adipotide is associated with prohibitin, a membrane protein receptor present in blood vessels of white fat tissues and some cancer cells.\u003c\/p\u003e\n\u003ch3\u003eFuture Research\u003c\/h3\u003e\n\u003cp class=\"white-back-d\" style=\"margin-bottom: 30px;\"\u003eAnti-angiogenic molecules like Adipotites target the blood vessels and are considered a potential agent in cancer studies.\u003csup\u003e[9]\u003c\/sup\u003e Most of the research with Adipotides have been focused on their potential in fat loss and diabetes. They have been suggested to target the blood vessels of adipose tissues in which they supposedly induce apoptosis.\u003c\/p\u003e\n\u003ch3 style=\"color: #555; margin-top: 25px;\"\u003eReferences\u003c\/h3\u003e\n\u003cdiv class=\"white-back-d\" style=\"padding-bottom: 5px !important; margin-bottom: 25px !important;\"\u003e\n\u003col style=\"color: #555;\"\u003e\n\u003cli\u003eKolonin, M. G., Saha, P. K., Chan, L., Pasqualini, R., \u0026amp; Arap, W. (2004). Reversal of obesity by targeted ablation of adipose tissue. Nature medicine, 10(6), 625–632.\u003c\/li\u003e\n\u003cli\u003eStaquicini, F. I., Cardó-Vila, M., Kolonin, M. G., Trepel, M., Edwards, J. K., Nunes, D. N., Sergeeva, A., Efstathiou, E., Sun, J., Almeida, N. F., Tu, S. M., Botz, G. H., Wallace, M. J., O'Connell, D. J., Krajewski, S., Gershenwald, J. E., Molldrem, J. J., Flamm, A. L., Koivunen, E., Pentz, R. D., … Arap, W. (2011). Vascular ligand-receptor mapping by direct combinatorial selection in cancer patients. \u003ci\u003eProceedings of the National Academy of Sciences of the United States of America\u003c\/i\u003e, \u003ci\u003e108\u003c\/i\u003e(46), 18637–18642.\u003c\/li\u003e\n\u003cli\u003eSalameh, A., Daquinag, A. C., Staquicini, D. I., An, Z., Hajjar, K. A., Pasqualini, R., Arap, W., \u0026amp; Kolonin, M. G. (2016). Prohibitin\/annexin 2 interaction regulates fatty acid transport in adipose tissue. \u003ci\u003eJCI insight\u003c\/i\u003e, \u003ci\u003e1\u003c\/i\u003e(10), e86351.\u003c\/li\u003e\n\u003cli\u003eKolonin, M. G., Saha, P. K., Chan, L., Pasqualini, R., \u0026amp; Arap, W. (2004). Reversal of obesity by targeted ablation of adipose tissue. \u003ci\u003eNature medicine\u003c\/i\u003e, \u003ci\u003e10\u003c\/i\u003e(6), 625–632.\u003c\/li\u003e\n\u003cli\u003eHossen, N., Kajimoto, K., Akita, H., Hyodo, M., \u0026amp; Harashima, H. (2013). A comparative study between nanoparticle-targeted therapeutics and bioconjugates as obesity medication. \u003ci\u003eJournal of controlled release : official journal of the Controlled Release Society\u003c\/i\u003e, \u003ci\u003e171\u003c\/i\u003e(2), 104–112.\u003c\/li\u003e\n\u003cli\u003eAllott, E. H., Masko, E. M., \u0026amp; Freedland, S. J. (2013). Obesity and prostate cancer: weighing the evidence. \u003ci\u003eEuropean urology\u003c\/i\u003e, \u003ci\u003e63\u003c\/i\u003e(5), 800–809.\u003c\/li\u003e\n\u003cli\u003eHossen, N., Kajimoto, K., Akita, H., Hyodo, M., \u0026amp; Harashima, H. (2013). A comparative study between nanoparticle-targeted therapeutics and bioconjugates as obesity medication. Journal of controlled release : official journal of the Controlled Release Society, 171(2), 104–112.\u003c\/li\u003e\n\u003cli\u003eBarnhart, K. F., Christianson, D. R., Hanley, P. W., Driessen, W. H., Bernacky, B. J., Baze, W. B., Wen, S., Tian, M., Ma, J., Kolonin, M. G., Saha, P. K., Do, K. A., Hulvat, J. F., Gelovani, J. G., Chan, L., Arap, W., \u0026amp; Pasqualini, R. (2011). A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys. Science translational medicine, 3(108), 108ra112.\u003c\/li\u003e\n\u003cli\u003eThuaud, F., Ribeiro, N., Nebigil, C. G., \u0026amp; Désaubry, L. (2013). Prohibitin ligands in cell death and survival: mode of action and therapeutic potential. Chemistry \u0026amp; biology, 20(3), 316–331.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"author-details\"\u003e\n\u003ch2\u003e\u003ca href=\"https:\/\/biotechpeptides.com\/dr-marinov\/\"\u003eDr. Usman\u003c\/a\u003e\u003c\/h2\u003e\n\u003cp\u003eDr. Usman (BSc, MBBS, MaRCP) completed his studies in medicine at the Royal College of Physicians, London. He is an avid researcher with more than 30 publications in internationally recognized peer-reviewed journals. Dr. Usman has worked as a researcher and a medical consultant for reputable pharmaceutical companies such as Johnson \u0026amp; Johnson and Sanofi.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"mysite","offers":[{"title":"Default Title","offer_id":51786429202749,"sku":"sku2194756126571","price":200.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0997\/4474\/3741\/files\/Adipotide-FTPP-10mg-2-1.webp?v=1780466160"},{"product_id":"aod-9604-5mg","title":"(🔥Fat loss) AOD 9604 (5mg) -10 Vials","description":"\u003cdiv class=\"et_pb_tab_content\"\u003e\n\u003cdiv class=\"pro-description-con\"\u003e\n\u003cp\u003e🧬 What is AOD-9604?\u003c\/p\u003e\n\u003cp\u003eFull name of AOD-9604:\u003cbr\u003e👉 Anti-Obesity Drug 9604\u003c\/p\u003e\n\u003cp\u003eEssentially:\u003c\/p\u003e\n\u003cp\u003eThe C-terminal fragment (177–191) of HGH\u003cbr\u003emodified for stability (more resistant to degradation)\u003cbr\u003e🔥 Primary functions (research focus)\u003cbr\u003e🧪 1️⃣ Promotes fat breakdown\u003c\/p\u003e\n\u003cp\u003eResearch suggests it may:\u003c\/p\u003e\n\u003cp\u003eEnhance fat oxidation\u003cbr\u003eInhibit lipogenesis\u003cbr\u003ePromote fatty acid release\u003c\/p\u003e\n\u003cp\u003e👉 Core positioning: “Fat-burning peptide”\u003c\/p\u003e\n\u003ch3\u003eAOD 9604 Peptide\u003c\/h3\u003e\n\u003cp class=\"white-back-d\" style=\"margin-bottom: 30px;\"\u003eAOD 9604 is a modified peptide initially developed as an offshoot in obesity research. It modifies the peptide of the growth hormone hGH by adding a tyrosine residue to the N-terminus. The proposed mode of action of AOD 9604 has been suggested by researchers to be restricted to promoting lipolysis, thus linking the synthetic compound to obesity research.\u003csup\u003e[1]\u003c\/sup\u003e The peptide does not appear to affect levels of insulin or IGF1 in studies thus far; therefore, it does not appear to trigger diabetes development or induce glucose intolerance in test models, though further studies are necessary to explore this aspect.\u003csup\u003e[2]\u003c\/sup\u003e\u003c\/p\u003e\n\u003ch3\u003eSpecifications\u003c\/h3\u003e\n\u003cp class=\"grey-back\"\u003e\u003cstrong\u003eOther Known Titles:\u003c\/strong\u003e AOD-9604\u003c\/p\u003e\n\u003cp class=\"white-back\"\u003e\u003cstrong\u003eMolecular Formula:\u003c\/strong\u003e C\u003csub\u003e78\u003c\/sub\u003eH\u003csub\u003e123\u003c\/sub\u003eN\u003csub\u003e23\u003c\/sub\u003eO\u003csub\u003e23\u003c\/sub\u003eS\u003csub\u003e2\u003c\/sub\u003e\u003c\/p\u003e\n\u003cp class=\"grey-back\"\u003e\u003cstrong\u003eMolecular Weight:\u003c\/strong\u003e 1815.1 g\/mol\u003c\/p\u003e\n\u003cp class=\"white-back\" style=\"margin-bottom: 30px;\"\u003e\u003cstrong\u003eSequence:\u003c\/strong\u003e Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe\u003c\/p\u003e\n\u003ch3\u003eAOD 9604 Research\u003c\/h3\u003e\n\u003cp class=\"grey-back-d\"\u003e\u003cstrong\u003eAOD 9604 Structure\u003c\/strong\u003e\u003cbr\u003eScientists hypothesize that different parts of the hGH molecule may possess different properties and induce different effects in test models.\u003csup\u003e[3]\u003c\/sup\u003e It has been suggested that only the last 15 amino acids may mediate any fat-burning potential of the hormone. The fragment was initially named hGH 177-191 and was subsequently modified by adding tyrosine to create AOD 9401, potentially to help stabilize the molecule. This modification led to the production of a 16-amino acid fragment called AOD 9604.\u003csup\u003e[4]\u003c\/sup\u003e Interestingly, the researchers comment, \u003cem\u003e\"AOD 9604 does not interact with the hGH receptor.”\u003c\/em\u003e This modification may have made the hGH Fragment 176-191 relatively more stable than other peptides.\u003c\/p\u003e\n\u003cp class=\"white-back-d\"\u003e\u003cstrong\u003eAOD 9604 Mechanism of Action\u003c\/strong\u003e\u003cbr\u003eAOD 9604 has mainly been studied in murine models, and significant experiments have involved relatively large amounts of AOD 9604.\u003csup\u003e[5]\u003c\/sup\u003e These experiments reportedly resulted in a 50% reduction in weight following exposure to the research models. However, it is important to note that the fragment appears to lack any other associated action of hGH, such as a potential increase of IGF-1 (insulin-like growth factor-1), insulin resistance, or cell proliferation. Therefore, the compound may not possess the potential muscle-preserving and anabolic action typically associated with growth hormones. Nevertheless, it appears that AOD 9604 may stimulate weight loss through mechanisms similar to hGH, as it may trigger various cellular pathways that might lead to the release of fatty acids from adipose cells.\u003cbr\u003e\u003cbr\u003eAdditionally, researchers have posited that the peptide may affect the activity of lipases, a group of enzymes that prevent the return of fat to adipose tissues.\u003csup\u003e[6]\u003c\/sup\u003e It is worth noting that AOD 9604 does not appear to affect natural hGH production and does not appear to act as a growth hormone secretagogue. Moreover, it does not appear to impact hunger hormone signaling to either increase or decrease appetite. Murine models comparing AOD 9604 and hGH have reported different outcomes in lean and obese cases.\u003csup\u003e[4]\u003c\/sup\u003e In lean murine models, hGH appears to increase lean body mass, whereas AOD 9604 or a placebo did not appear to produce the same action. Hence, researchers have speculated that AOD 9604 may not be effective in increasing the size of muscle cells and contributing to muscle hypertrophy. However, in obese murine models, both hGH and AOD 9604 appear to exert a weight loss potential. The scientists also commented that there was an apparent 40% reduction in adipose tissue in the hGH group compared to 28% with AOD 9604.\u003cbr\u003e\u003cbr\u003eTherefore, experiments suggest that AOD 9604 may hold reduced potential compared to hGH in stimulating the release of fats from adipose cells.\u003csup\u003e[7]\u003c\/sup\u003e The researchers also posit that \u003cem\u003e“the lipolytic actions of both hGH and AOD 9604 are not mediated directly through the β3-AR although both compounds increase β3-AR expression, which may subsequently contribute to enhanced lipolytic sensitivity.”\u003c\/em\u003e Growth hormone likely promotes a greater release of fats from adipose cells due to its proposed impact on insulin resistance. By reducing glucose uptake, it may force cells to potentially utilize more fat instead. In contrast, the fragment AOD 9604 does not appear to increase insulin resistance. Additionally, anecdotal data suggests that AOD 9604 may potentially offer some impact, including modest improvements in cholesterol levels and insulin sensitivity, but it is yet to be confirmed by murine models.\u003c\/p\u003e\n\u003cp class=\"grey-back-d\"\u003e\u003cstrong\u003eAOD 9604 and Obesity\u003c\/strong\u003e\u003cbr\u003eAOD 9604 has been brought into clinical trials with the objective of targeting obesity using a peptide similar to hGH. Phase 2b clinical trials conducted on 300 obese test subjects in Australia observed that the peptide appeared to result in consistent weight loss over 12 weeks when introduced once daily.\u003csup\u003e[8]\u003c\/sup\u003e The rate of weight reduction in test subjects was consistently compared to the placebo cohort, and weight loss appeared to hold steady over the entire study period. This observation indicated that the peptide is unlikely to generate resistance, and thus continued influence of the peptide might result in a pronounced effect. Study in this area is ongoing. Researchers have also utilized mice models to explore the underlying mechanism of AOD 9604.\u003cbr\u003e\u003cbr\u003eAn initial hypothesis proposed that AOD 9604 may bind and activate β-3-adrenergic receptors, which are present on the surface of white adipose tissues. Upon binding to the cognate receptors, the peptide may trigger downstream signaling, which may mobilize the fat cells from storage mode to a usable state by enhancing the rate of metabolism. Interestingly, mice genetically mutated in β-3-adrenergic receptors underwent fat loss, possibly through apoptosis of the white adipose tissues.\u003c\/p\u003e\n\u003cp class=\"white-back-d\"\u003e\u003cstrong\u003eAOD 9604 and Cardiac Disease\u003c\/strong\u003e\u003cbr\u003eAOD 9604 may host the potential to improve cardiac function indirectly by mobilizing fat and reducing obesity. The peptide may reduce the chances of cardiac disease induced by obesity. Apart from its proposed principal function of decreasing fat burden, research teams have suggested other mechanisms by which the peptide might improve cardiac conditions. These pathways are independent of β-3-adrenergic receptors and appear to improve general metabolism, improving cardiac function.\u003csup\u003e[9]\u003c\/sup\u003e\u003c\/p\u003e\n\u003cp class=\"grey-back-d\" style=\"margin-bottom: 30px;\"\u003e\u003cstrong\u003eAOD 9604 and Joints\u003c\/strong\u003e\u003cbr\u003eResearch suggests that AOD 9604 may influence arthritic joints in rabbits, and may have contributed to an improvement in pain perception and decreased movement disability.\u003csup\u003e[10]\u003c\/sup\u003e Researchers have speculated that AOD 9604 may promote the growth of cartilage tissue in the arthritic joints but have yet to fully investigate this hypothesis. Experimental examination and microscopic cartilage structure analysis in affected joints have indicated positive results upon AOD 9604 influence in osteoarthritis test subjects.\u003c\/p\u003e\n\u003ch3 style=\"color: #555;\"\u003eReferences\u003c\/h3\u003e\n\u003cdiv class=\"white-back-d\" style=\"padding-bottom: 5px !important; margin-bottom: 25px !important;\"\u003e\n\u003col style=\"color: #555;\"\u003e\n\u003cli\u003eNg, F. M., Sun, J., Sharma, L., Libinaka, R., Jiang, W. J., \u0026amp; Gianello, R. (2000). Metabolic studies of a synthetic lipolytic domain (AOD 9604) of human growth hormone. Hormone research, 53(6), 274–278.\u003c\/li\u003e\n\u003cli\u003eCox, H. D., Smeal, S. J., Hughes, C. M., Cox, J. E., \u0026amp; Eichner, D. (2015). Detection and in vitro metabolism of AOD 9604. Drug testing and analysis, 7(1), 31–38.\u003c\/li\u003e\n\u003cli\u003eNg, F. M., Jiang, W. J., Gianello, R., Pitt, S., \u0026amp; Roupas, P. (2000). Molecular and cellular actions of a structural domain of human growth hormone (AOD9401) on lipid metabolism in Zucker fatty rats. \u003ci\u003eJournal of molecular endocrinology\u003c\/i\u003e, \u003ci\u003e25\u003c\/i\u003e(3), 287-298.\u003c\/li\u003e\n\u003cli\u003eHeffernan, M. A., Thorburn, A. W., Fam, B., Summers, R., Conway-Campbell, B., Waters, M. J., \u0026amp; Ng, F. M. (2001). Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. \u003ci\u003eInternational journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity\u003c\/i\u003e, \u003ci\u003e25\u003c\/i\u003e(10), 1442–1449.\u003c\/li\u003e\n\u003cli\u003eNg, F. M., Sun, J., Sharma, L., Libinaka, R., Jiang, W. J., \u0026amp; Gianello, R. (2000). Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. \u003ci\u003eHormone research\u003c\/i\u003e, \u003ci\u003e53\u003c\/i\u003e(6), 274–278.\u003c\/li\u003e\n\u003cli\u003eKopchick, J. J., Berryman, D. E., Puri, V., Lee, K. Y., \u0026amp; Jorgensen, J. O. (2020). The effects of growth hormone on adipose tissue: old observations, new mechanisms. \u003ci\u003eNature Reviews Endocrinology\u003c\/i\u003e, \u003ci\u003e16\u003c\/i\u003e(3), 135-146.\u003c\/li\u003e\n\u003cli\u003eHeffernan, M., Summers, R. J., Thorburn, A., Ogru, E., Gianello, R., Jiang, W. J., \u0026amp; Ng, F. M. (2001). The Effects of Human GH and Its Lipolytic Fragment (AOD9604) on Lipid Metabolism Following Chronic Treatment in Obese Mice andβ 3-AR Knock-Out Mice. \u003ci\u003eEndocrinology\u003c\/i\u003e, \u003ci\u003e142\u003c\/i\u003e(12), 5182-5189.\u003c\/li\u003e\n\u003cli\u003eBray, G. A., \u0026amp; Greenway, F. L. (2007). Pharmacological treatment of the overweight patient. Pharmacological reviews, 59(2), 151–184.\u003c\/li\u003e\n\u003cli\u003eHeffernan, M., Summers, R. J., Thorburn, A., Ogru, E., Gianello, R., Jiang, W. J., \u0026amp; Ng, F. M. (2001). The effects of human GH and its lipolytic fragment (AOD 9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology, 142(12), 5182–5189.\u003c\/li\u003e\n\u003cli\u003eKwon, D. R., \u0026amp; Park, G. Y. (2015). Effect of Intra-articular Injection of AOD 9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model. Annals of clinical and laboratory science, 45(4), 426–432.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"author-details\"\u003e\n\u003cp\u003eDr. Usman (BSc, MBBS, MaRCP) completed his studies in medicine at the Royal College of Physicians, London. He is an avid researcher with more than 30 publications in internationally recognized peer-reviewed journals. Dr. Usman has worked as a researcher and a medical consultant for reputable pharmaceutical companies such as Johnson \u0026amp; Johnson and Sanofi.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"mysite","offers":[{"title":"Default Title","offer_id":51786429268285,"sku":"sku2194756125337","price":120.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0997\/4474\/3741\/files\/AOD-9604-5mg-2-1.webp?v=1780466162"},{"product_id":"tesamorelin","title":"(🔥Reduce visceral fat) Tesamorelin Peptide (5MG \u0026 10MG) -10 Vials","description":"\u003cdiv class=\"et_pb_tab_content\"\u003e\n\u003cdiv class=\"pro-description-con\"\u003e\n\u003ch3\u003eReduce deep abdominal fat\u003cbr\u003eGet rid of a “beer belly”\u003cbr\u003eReduce the accumulation of visceral fat\u003cbr\u003e\u003cbr\u003eTesamorelin Peptide\u003c\/h3\u003e\n\u003cp style=\"margin-bottom: 30px;\" class=\"white-back-d\"\u003eTesamorelin is a chemically altered growth hormone-releasing hormone (GHRH) analog, that similar to the original is made of 44 amino acids. This peptide is a trans-3-hexanoic acid version of natural GHRH. The trans-3-hexanoic acid group is added to the N-terminus, while the C-terminus is amidated and acetylated. Tesamorelin appears to mediate the positive influence of GHRH and other GHRH analogs such as GRF (1-29), CJC-1295, and . The trans-3-hexanoic acid modification may increase its stability and half-life. Both Tesamorelin and CJC-1295 appear to maintain the physiological activity of GHRH, without disrupting the physiological rhythm of GH release.\u003c\/p\u003e\n\u003ch3\u003eSpecifications\u003c\/h3\u003e\n\u003cp class=\"white-back\"\u003e\u003cstrong\u003eMolecular Formula:\u003c\/strong\u003e C\u003csub\u003e221\u003c\/sub\u003eH\u003csub\u003e366\u003c\/sub\u003eN\u003csub\u003e72\u003c\/sub\u003eO\u003csub\u003e67\u003c\/sub\u003eS\u003c\/p\u003e\n\u003cp class=\"grey-back\"\u003e\u003cstrong\u003eMolecular Weight:\u003c\/strong\u003e 5136 g\/mol\u003c\/p\u003e\n\u003cp style=\"margin-bottom: 30px;\" class=\"white-back\"\u003e\u003cstrong\u003eSequence:\u003c\/strong\u003e trans-hexenoyl-acid-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-AsnSer-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-LeuGln-Asp-Ile-Met-Ser-Arg-GlnGln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu\u003c\/p\u003e\n\u003ch3\u003eTesamorelin Research\u003c\/h3\u003e\n\u003cp class=\"white-back-d\"\u003e\u003cstrong\u003eTesamorelin and the Pituitary Gland\u003c\/strong\u003e\u003cbr\u003eTesamorelin might potentially interact with the pituitary gland by possibly binding to GHRH receptors, which might initiate a sequence of molecular events. Researchers propose that it may cause structural alterations in the receptor, thereby activating intracellular signaling pathways.\u003csup\u003e[1, 2]\u003c\/sup\u003e They have noted that this binding process is likely followed by a significant conformational change, involving the transmembrane helix 6 (TM6), which may open the intracellular face for G protein coupling. One potential pathway might involve the stimulation of cyclic adenosine monophosphate (cAMP) production within pituitary cells. This might be achieved through the activation of the enzyme adenylate cyclase, which may convert ATP (adenosine triphosphate) to cAMP. It is suggested that increased cAMP levels might activate protein kinase A (PKA), leading to protein phosphorylation and GHRH receptor activation by Tesamorelin. This cascade might stimulate the synthesis and secretion of growth hormone (hGH) from somatotrophs in the pituitary gland. Research indicates that Tesamorelin may induce up to a 69% rise in overall growth hormone levels, as measured by the 12-hour area under the curve (AUC), which quantifies the total hormone concentration over 12 hours. Additionally, there may be approximately a 55% increase in the average pulse area of growth hormone, which reflects the amount of hormone released during each pulse. Furthermore, levels of insulin-like growth factor 1 (IGF-1) apparently surged by 122%.\u003csup\u003e[3]\u003c\/sup\u003e\u003c\/p\u003e\n\u003cp class=\"grey-back-d\"\u003e\u003cstrong\u003eTesamorelin and Growth Hormone Deficiency, HIV\u003c\/strong\u003e\u003cbr\u003eHighly active antiretroviral therapy (HAART) may trigger endocrine and metabolic disorders, including growth hormone (GH) deficiency. In cases of HIV infection, the pituitary gland function may be altered, inducing a general growth hormone deficiency in one-third of research models used to study the impacts of HAART.\u003csup\u003e[4]\u003c\/sup\u003e Tesamorelin has been employed in research to measure its potential impact in supplementing growth hormone deficiency by inducing natural hormone production.\u003c\/p\u003e\n\u003cp class=\"white-back-d\"\u003e\u003cstrong\u003eTesamorelin and Lipodystrophy\u003c\/strong\u003e\u003cbr\u003eTesamorelin is principally researched within the context of HIV-associated lipodystrophy, which is considered to be caused by viral infection and possible adverse consequences of certain antiretroviral procedures. Lipodystrophy is characterized by an irregular distribution and storage of fat cells, which can often result in visceral obesity. Visceral obesity refers to the abnormal accumulation of fat around and within internal organs, and it has been tentatively linked to a range of metabolic disturbances. These disturbances may include insulin resistance, which impairs the organism’s ability to regulate blood sugar levels; elevated levels of low-density lipoprotein (LDL) cholesterol, often referred to as \"bad\" cholesterol due to its association with increased risk of cardiovascular disease; and hyperuricemia, which is an excessive concentration of uric acid in the blood. Tesamorelin has been hypothesized to potentially mitigate these metabolic disturbances due to its speculated action on adiposity. The peptide appeared to reduce adiposity by up to 20% of the models examined in one study.\u003csup\u003e[5]\u003c\/sup\u003e The researchers noted that \u003cem\u003e“The odds of response of VAT ‹140 cm2 was 3.9 times greater for Tesamorelin-... [cases] than … the control.” \u003c\/em\u003eAnother experiment that lasted for over 52 weeks and involved over 800 research models suggested that the peptide may lead to a mean of -17.5% reduction in visceral adiposity. In addition there were apparent reductions in triglycerides by a mean of -48 mg\/dl, cholesterol by a mean of -8 mg\/dl, and non-high-density lipoprotein by a mean of -7 mg\/dl.\u003csup\u003e[6]\u003c\/sup\u003e Further research into Tesamorelin that has involved reviews of multiple experiments has suggested it may lead to an apparent reduction of up to -25% reduction in visceral fat among lipodystrophy models.\u003csup\u003e[7]\u003c\/sup\u003e\u003c\/p\u003e\n\u003cp class=\"grey-back-d\"\u003e\u003cstrong\u003eTesamorelin and Cholesterol Metabolism\u003c\/strong\u003e\u003cbr\u003eEctopic fat deposition, such as in visceral organs, epicardium, and liver, has been linkedto elevated inflammation, which may increase the risk of lipids and cholesterol imbalance. Tesamorelin studies posit that the peptide may reduce triglyceride, total cholesterol, and non-HDL-C.\u003csup\u003e[8]\u003c\/sup\u003e The peptide may potentially decrease inflammatory response through the control of excess adiposity.\u003csup\u003e[9]\u003c\/sup\u003e The researchers note that \u003cem\u003e“[models exposed to] Tesamorelin with ≥8% reduction in VAT have significantly improved triglyceride levels, adiponectin levels, and preservation of glucose homeostasis over 52 weeks.”\u003c\/em\u003e\u003c\/p\u003e\n\u003cp class=\"white-back-d\"\u003e\u003cstrong\u003eTesamorelin and Peripheral Nerve Damage\u003c\/strong\u003e\u003cbr\u003ePeripheral nerve damage may potentially trigger debilitating motor and sensory challenges. Research in intervention of such damage is limited, as nerve cells present a challenge to regenerate. Studies suggest that growth hormone manipulation might improve peripheral nerve injury and increase both rate and extent of repair.\u003csup\u003e[10]\u003c\/sup\u003e Tesamorelin is being actively researched in this area for its potential for inducing growth hormone release.\u003c\/p\u003e\n\u003cp class=\"grey-back-d\"\u003e\u003cstrong\u003eTesamorelin and Neurodegenerative Issues\u003c\/strong\u003e\u003cbr\u003eGHRH analogs, including Tesamorelin, have been researched for their potential to improve cognitive ability in dementia models. A randomized, double-blind, placebo-controlled study was conducted with a large cohort over a period of 20 weeks at The University of Washington School of Medicine. The study observed that Tesamorelin and other GHRH analogs may influence dementia by increasing gamma-aminobutyric acid (GABA) in the brain and decreasing myo-insoitol (MI).\u003csup\u003e[11]\u003c\/sup\u003e These findings suggest greater avenues of potential for Tesamorelin research.\u003c\/p\u003e\n\u003cp class=\"white-back-d\"\u003e\u003cstrong\u003eTesamorelin and Muscle Anabolism\u003c\/strong\u003e\u003cbr\u003eA research study was conducted to explore the potential of Tesamorelin on the structural quality of muscle tissues, using computed tomography (CT) scans.\u003csup\u003e[12]\u003c\/sup\u003e The findings from this study indicated a possible association between Tesamorelin and improvements in muscle tissue density and volume. Specifically, the study observed that certain muscle groups, namely the rectus abdominis, psoas major, and paraspinal muscles, exhibited more pronounced changes which included either an increase in muscle density and volume or a reduction in intramuscular fat content. From a statistical standpoint, the differences in muscle density and size, as well as the decrease in fat content within these muscles, were significantly greater than those observed in a control group.\u003c\/p\u003e\n\u003cp style=\"margin-bottom: 30px;\" class=\"grey-back-d\"\u003e\u003cstrong\u003eTesamorelin and Liver Adiposity\u003c\/strong\u003e\u003cbr\u003eResearch has indicated that Tesamorelin might lower hepatic fat fraction (HFF). \u003csup\u003e[13]\u003c\/sup\u003e The study observed a reduction in absolute hepatic fat by 4.7% among Tesamorelin-exposed models, while the control group exhibited no change. This represents a relative decrease in liver fat by 37%, which might suggest a potential benefit in reducing liver fat accumulation. Furthermore, 35% of the Tesamorelin group achieved a hepatic fat fraction below 5%, in contrast to just 4% in the control. In terms of liver tissue fibrosis, Tesamorelin appeared to slow its progression, with only 10.5% of the Tesamorelin group showing fibrosis progression, compared to 37.5% in the placebo. Nevertheless, Tesamorelin did not seem to significantly improve pre-existing fibrosis. The observed reduction in liver fat was correlated with improvements in fibrosis, hinting at a possible mechanistic connection between reduced liver fat and decreased fibrosis progression. Additionally, Tesamorelin appeared to exhibit anti-inflammatory properties, as indicated by reductions in c-reactive protein (CRP) levels. Despite these promising findings, Tesamorelin did not significantly impact liver enzymes, such as alanine aminotransferase (ALT) and gamma-glutamyl transferase (GGT), overall. However, it did reduce ALT levels in models of elevated baseline levels. Metabolic parameters, including fasting glucose and hemoglobin A1c, were not significantly altered, suggesting that Tesamorelin might have a neutral action on glucose regulation during the study period.\u003c\/p\u003e\n\u003cp\u003e\u003cb\u003e\u003cem\u003eDisclaimer:  Research chemicals are intended solely for laboratory experimentation and\/or in-vitro testing. Bodily introduction of any sort is strictly prohibited by law. All purchases are limited to licensed researchers and\/or qualified professionals. All information shared in this article is for educational purposes only.\u003c\/em\u003e\u003c\/b\u003e\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003ch3 style=\"color: #555;\"\u003eReferences\u003c\/h3\u003e\n\u003cdiv style=\"padding-bottom: 5px !important; margin-bottom: 25px !important;\" class=\"white-back-d\"\u003e\n\u003col style=\"color: #555;\"\u003e\n\u003cli\u003eSpooner, L. M., \u0026amp; Olin, J. L. (2012). Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy. The Annals of pharmacotherapy, 46(2), 240–247.\u003c\/li\u003e\n\u003cli\u003eZhou, F., Zhang, H., Cong, Z., Zhao, L. H., Zhou, Q., Mao, C., Cheng, X., Shen, D. D., Cai, X., Ma, C., Wang, Y., Dai, A., Zhou, Y., Sun, W., Zhao, F., Zhao, S., Jiang, H., Jiang, Y., Yang, D., Eric Xu, H., … Wang, M. W. (2020). Structural basis for activation of the growth hormone-releasing hormone receptor. Nature communications, 11(1),\u003c\/li\u003e\n\u003cli\u003eStanley TL, Chen CY, Branch KL, Makimura H, Grinspoon SK. Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men. J Clin Endocrinol Metab. 2011 Jan;96(1):150-8. . Epub 2010 Oct 13. PMID: 20943777; PMCID: PMC3038486.\u003c\/li\u003e\n\u003cli\u003eRochira, V., \u0026amp; Guaraldi, G. (2017). Growth hormone deficiency and immunodeficiency virus. Best practice \u0026amp; research. Clinical endocrinology \u0026amp; metabolism, 31(1), 91–111. .\u003c\/li\u003e\n\u003cli\u003eMangili, A., Falutz, J., Mamputu, J. C., Stepanians, M., \u0026amp; Hayward, B. (2015). Predictors of Treatment Response to Tesamorelin, a Growth Hormone-Releasing Factor Analog, in HIV-Infected Patients with Excess Abdominal Fat. PloS one, 10(10), e0140358. .\u003c\/li\u003e\n\u003cli\u003eFalutz J, Mamputu JC, Potvin D, Moyle G, Soulban G, Loughrey H, Marsolais C, Turner R, Grinspoon S. Effects of Tesamorelin (TH9507), a growth hormone-releasing factor analog, in immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab. 2010 Sep;95(9):4291-304. . Epub 2010 Jun 16. PMID: 20554713.\u003c\/li\u003e\n\u003cli\u003eSivakumar T, Mechanic O, Fehmie DA, Paul B. Growth hormone axis treatments for HIV-associated lipodystrophy: a systematic review of placebo-controlled trials. HIV Med. 2011 Sep;12(8):453-62. doi: 10.1111\/j.1468-1293.2010.00906.x. Epub 2011 Jan 25. PMID: 21265979.\u003c\/li\u003e\n\u003cli\u003eFalutz, J., Allas, S., Blot, K., Potvin, D., Kotler, D., Somero, M., Berger, D., Brown, S., Richmond, G., Fessel, J., Turner, R., \u0026amp; Grinspoon, S. (2007). Metabolic effects of a growth hormone-releasing factor in patients with HIV. The New England journal of medicine, 357(23), 2359–2370. .\u003c\/li\u003e\n\u003cli\u003eStanley, T. L., Falutz, J., Marsolais, C., Morin, J., Soulban, G., Mamputu, J. C., Assaad, H., Turner, R., \u0026amp; Grinspoon, S. K. (2012). Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving Tesamorelin. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 54(11), 1642–1651. .\u003c\/li\u003e\n\u003cli\u003eTuffaha, S. H., Singh, P., Budihardjo, J. D., Means, K. R., Higgins, J. P., Shores, J. T., Salvatori, R., Höke, A., Lee, W. P., \u0026amp; Brandacher, G. (2016). Therapeutic augmentation of the growth hormone axis to improve outcomes following peripheral nerve injury. Expert opinion on therapeutic targets, 20(10), 1259–1265. .\u003c\/li\u003e\n\u003cli\u003eFriedman, S. D., Baker, L. D., Borson, S., Jensen, J. E., Barsness, S. M., Craft, S., Merriam, G. R., Otto, R. K., Novotny, E. J., \u0026amp; Vitiello, M. V. (2013). Growth hormone-releasing hormone effects on brain γ-aminobutyric acid levels in mild cognitive impairment and healthy aging. JAMA neurology, 70(7), 883–890. .\u003c\/li\u003e\n\u003cli\u003eAdrian S, Scherzinger A, Sanyal A, Lake JE, Falutz J, Dubé MP, Stanley T, Grinspoon S, Mamputu JC, Marsolais C, Brown TT, Erlandson KM. The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV. J Frailty Aging. 2019;8(3):154-159. \u003ca rel=\"noopener\" href=\"https:\/\/doi.org\/10.14283\/jfa.2018.45\" target=\"_blank\"\u003edoi: 10.14283\/jfa.2018.45\u003c\/a\u003e. PMID: 31237318; PMCID: PMC6766405.\u003c\/li\u003e\n\u003cli\u003eStanley, T. L., Fourman, L. T., Feldpausch, M. N., Purdy, J., Zheng, I., Pan, C. S., Aepfelbacher, J., Buckless, C., Tsao, A., Kellogg, A., Branch, K., Lee, H., Liu, C. Y., Corey, K. E., Chung, R. T., Torriani, M., Kleiner, D. E., Hadigan, C. M., \u0026amp; Grinspoon, S. K. (2019). Effects of Tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. The lancet. HIV, 6(12), e821–e830.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003c\/div\u003e\n\u003cdiv\u003eAll orders ship same day if placed by 12 PST.\u003c\/div\u003e\n\u003cdiv class=\"vbni\"\u003e\u003cem\u003e Only qualified and licensed professionals should handle these products. Any information found on Biotech Peptides is strictly for educational purposes only. Refer to our \u003ca href=\"https:\/\/biotechpeptides.com\/terms-and-conditions\/\"\u003eterms and conditions\u003c\/a\u003e for more details.\u003c\/em\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"author-details\"\u003e\n\u003ch2\u003e\u003ca href=\"https:\/\/biotechpeptides.com\/dr-marinov\/\"\u003eDr. Usman\u003c\/a\u003e\u003c\/h2\u003e\n\u003cp\u003eDr. Usman (BSc, MBBS, MaRCP) completed his studies in medicine at the Royal College of Physicians, London. He is an avid researcher with more than 30 publications in internationally recognized peer-reviewed journals. Dr. Usman has worked as a researcher and a medical consultant for reputable pharmaceutical companies such as Johnson \u0026amp; Johnson and Sanofi.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"mysite","offers":[{"title":"10mg","offer_id":51786429661501,"sku":"sku2194756148783","price":160.0,"currency_code":"USD","in_stock":true},{"title":"5mg","offer_id":51786429694269,"sku":"sku2194756148784","price":120.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0997\/4474\/3741\/files\/TESAMORELIN-1-1.webp?v=1780466166"},{"product_id":"fragment-176-191-5mg","title":"（🔥Fat Loss） Fragment 176-191 (5mg) - 10 Vials","description":"\u003cdiv class=\"et_pb_tab_content\"\u003e\n\u003cp\u003e🧬 What is Fragment 176–191?\u003c\/p\u003e\n\u003cp\u003eIt is the segment of the HGH (human growth hormone) molecule comprising:\u003c\/p\u003e\n\u003cp\u003e👉 Amino acids 176 through 191\u003c\/p\u003e\n\u003cp\u003eScientists have discovered that:\u003c\/p\u003e\n\u003cp\u003eThis region is primarily associated with “lipolysis”\u003cbr\u003eIt does not contribute to IGF-1 growth or bone growth\u003c\/p\u003e\n\u003cp\u003eTherefore, it has been isolated for separate study.\u003c\/p\u003e\n\u003cp\u003e🔥 Main Effects (Theory + Animal Studies)\u003cbr\u003e🧪 1️⃣ Promotes lipolysis\u003c\/p\u003e\n\u003cp\u003eStudies suggest it may:\u003c\/p\u003e\n\u003cp\u003eIncrease fat oxidation\u003cbr\u003eInhibit lipogenesis\u003cbr\u003ePromote the release of fatty acids from fat cells\u003c\/p\u003e\n\u003cp\u003e👉 Core Goal: Fat Loss\u003c\/p\u003e\n\u003ch2\u003eFragment 176-191 Peptide\u003c\/h2\u003e\n\u003cp class=\"white-back-d\" style=\"margin-bottom: 30px;\"\u003eFragment 176-191 peptide (Frag 176-191) is a short segment of growth hormone (hGH) and is sometimes referred to as the “\u003cem\u003elipolytic fragment\u003c\/em\u003e.” The name was coined from initial research on animal systems, which suggested that Fragment 176-191 may potentially increase fat cell metabolism in genetically engineered obese mice. Growth hormone (hGH) supplementation is considered by scientists to generally suppress carbohydrate metabolism, alter sensitivity towards insulin, promote long bone growth, and heighten insulin-like growth factor-1 (IGF-1) levels. Extensive animal studies have suggested that this synthetic fragment may mimic the lipolytic action of hGH without other actions.\u003csup\u003e[1]\u003c\/sup\u003e\u003c\/p\u003e\n\u003ch3\u003eSpecifications\u003c\/h3\u003e\n\u003cp class=\"white-back\"\u003e\u003cstrong\u003eMolecular Formula:\u003c\/strong\u003e C\u003csub\u003e78\u003c\/sub\u003eH\u003csub\u003e125\u003c\/sub\u003eN\u003csub\u003e23\u003c\/sub\u003eO\u003csub\u003e23\u003c\/sub\u003eS\u003csub\u003e2\u003c\/sub\u003e\u003c\/p\u003e\n\u003cp class=\"grey-back\"\u003e\u003cstrong\u003eMolecular Weight:\u003c\/strong\u003e 1817.1 g\/mol\u003c\/p\u003e\n\u003cp class=\"grey-back\"\u003e\u003cstrong\u003eSequence:\u003c\/strong\u003e Tyr-Leu-Arg-Ile-Val-Gin-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe\u003c\/p\u003e\n\u003cp class=\"white-back\" style=\"margin-bottom: 30px;\"\u003e\u003cstrong\u003eOther Known Titles:\u003c\/strong\u003e Frag 176-191\u003c\/p\u003e\n\u003ch3\u003eFragment 176-191 Research\u003c\/h3\u003e\n\u003cp class=\"grey-back-d\"\u003e\u003cstrong\u003eFragment 176-191 Structure\u003c\/strong\u003e\u003cbr\u003eFragment 176-191 is the shortened C-terminal fragment of hGH, encompassing a sequence of 16 amino acids. Researchers who synthesized the peptide assert that the structure corresponds to the final 16 amino acids of the hGH molecule and the peptide, therefore, is speculated to act as the \"\u003cem\u003elipolytic fragment\u003c\/em\u003e\" of hGH. The designation \"\u003cem\u003elipolytic\u003c\/em\u003e\" indicates that this fragment may have characteristics that facilitate the degradation of lipids or fats. In an aim to improve the stability of this peptide, the first amino acid in the sequence of hGH Fragment 176-191 has been replaced with tyrosine. As a result, this altered peptide is sometimes also known as Fragment tyr-hGH 177-191 or . Incorporating tyrosine at the N-terminus is thought to bolster the peptide's stability. Additionally, preliminary data suggests a naturally occurring disulfide bond between two cysteine amino acids in the original hGH and in Frag 176-191. This disulfide bond is presumed to play a role in maintaining the structural integrity of the molecule, thereby possibly enhancing its resilience and capacity to resist degradation under various environmental conditions, such as exposure to gastric acids and digestive enzymes.\u003csup\u003e[2]\u003c\/sup\u003e\u003c\/p\u003e\n\u003cp class=\"white-back-d\"\u003e\u003cstrong\u003eFragment 176-191 and Cartilage\u003c\/strong\u003e\u003cbr\u003eExperimental research in Fragment 176-191 suggests its potential in cartilage regeneration.\u003csup\u003e[3]\u003c\/sup\u003e To investigate the potential action of this peptide on knee osteoarthritis, scientists employed a model to mimic the condition by damaging knee cartilage by introducing type II collagenase. This particular enzyme is speculated to act in degrading the cartilage cellular matrix, mimicking the pathological changes seen in osteoarthritis. After inducing cartilage damage, the damaged knee models were organized into four distinct groups for 4-7 weeks: the researchers exposed the first group to a control compound saline (Group 1), the second was exposed to hyaluronic acid (Group 2), the third experimental group was exposed to Fragment 176-191 peptide (Group 3), and the fourth group was exposed to a combination of Fragment 176-191 peptide and hyaluronic acid (Group 4). To assess the potential actions of these experimental interventions, the severity of cartilage damage was systematically evaluated using both morphological and histopathological methods. Additionally, the extent of lameness was measured eight weeks post-initiation of the experimental protocols, providing insights into the functional outcomes of the interventions. The researchers commented, \"\u003cem\u003eMean gross morphological and histopathological scores were significantly higher in Group 1 than in Groups 2, 3, and 4, and the scores were significantly lower in Group 4 than in Groups 2 and 3. The lameness period in Group 4 was significantly shorter than those in Groups 1, 2, and 3.\u003c\/em\u003e” The findings indicate that both the hyaluronic acid and the Fragment 176-191 peptide may exhibit superior potential compared to saline in promoting cartilage regeneration. This hypothesis stems from the posited interactions between these two compounds, where hyaluronic acid may support moisture retention and lubrication, while Fragment 176-191 may play a role in the regeneration and repair of the model tissues.\u003c\/p\u003e\n\u003cp class=\"grey-back-d\"\u003e\u003cstrong\u003eFragment 176-191 and Hypoglycemia\u003c\/strong\u003e\u003cbr\u003eThe C terminal end of hGH principally has been considered to bring about hypoglycemic (low blood sugar) levels in murine models.\u003csup\u003e[4]\u003c\/sup\u003e Screening of at least six different fragments obtained from the C terminal section of hGH has suggested that Fragment 176-191 may be a potentially effective synthetic derivative of hGH in research on blood sugar control. The hypoglycemic potential is considered secondary to maintaining an increased expression of insulin in blood plasma.\u003c\/p\u003e\n\u003cp class=\"white-back-d\"\u003e\u003cstrong\u003eFragment 176-191 and Fat Cells\u003c\/strong\u003e\u003cbr\u003eThe fat cell dissolution potential of Fragment 176-191 stems from research hypothesizing the peptide’s capacity to increase the production of beta-3 adrenergic receptors (3-AR or ADRB3).\u003csup\u003e[5]\u003c\/sup\u003e More specifically, the researchers posted that Fragment 176-191 may be “\u003cem\u003ecapable of increasing the repressed levels of beta(3)-AR RNA in obese mice to levels comparable with those in lean mice.\u003c\/em\u003e” An elevated density of beta-3 adrenergic receptors on adipocyte membranes potentially heightens these cells' sensitivity to lipolytic cues. This implies that although Fragment 176-191 might not interact directly with ADRB3, the increased number of these receptors might amplify the lipolytic activity prompted by endogenous catecholamines, notably adrenaline, which is posited to activate these receptors directly. Thus, agonist activity of the Fragment 176-191 peptide upon interaction with ADRB3 appeared to directly enhance fat burning in adipose tissue. Fragment 176-191 might initiate additional cellular signaling pathways that may indirectly enhance fat metabolism. For example, it might influence processes that either elevate the production of key enzymes involved in lipolysis or potentially enhance the cell's responsiveness to lipolytic signals through the regulation of secondary messengers within the cell. Here, lipolysis is the process of fat breakdown occurring in adipocytes, primarily driven by lipolytic enzymes. Secondary messengers are intracellular molecules believed to intensify signals from cell surface receptors to the internal biochemical systems. This amplification is crucial for orchestrating intricate cellular reactions to external signals. Research indicates that genetically modified mice that lack ADRB3 may be resistant to the action of hGH \/ Fragment 176-191. One experimental study observed that Fragment 176-191 exposure appeared to induce up to 50% weight reduction in obese mice over three weeks. Interestingly, the peptide appeared to mediate weight reduction only in obese mice but not in lean mice during the same span of exposure. The results suggest that secondary pathways may be involved in energy homeostasis, which may be capable of maintaining fat reserve in lean mice by overriding the ADRB3 pathway.\u003c\/p\u003e\n\u003cp class=\"grey-back-d\" style=\"margin-bottom: 30px;\"\u003e\u003cstrong\u003eFragment 176-191 and Fat Tissue Mass\u003c\/strong\u003e\u003cbr\u003eIn the realm of scientific inquiry, the potential of Fragment 176-191 in reducing total levels of fat mass has been probed using rigorously structured clinical trials, such as the METAOD005 study. This specific trial aimed to assess the efficacy of the peptide in reducing adipose tissue over a period of 12 weeks. Preliminary findings suggest that test subjects in one of the Fragment 176-191 groups may have experienced a notable reduction in fat tissue mass, with an average weight loss of approximately 5.7 pounds. Furthermore, there is a tentative suggestion that this peptide might positively influence lipid and glucose metabolism. However, additional studies are necessary to thoroughly explore these possibilities.\u003csup\u003e[6]\u003c\/sup\u003e\u003c\/p\u003e\n\u003ch3 style=\"color: #555;\"\u003eReferences\u003c\/h3\u003e\n\u003cdiv class=\"white-back-d\" style=\"margin-bottom: 30px;\"\u003e\n\u003col style=\"color: #555;\"\u003e\n\u003cli\u003eHabibullah MM, Mohan S, Syed NK, Makeen HA, Jamal QMS, Alothaid H, Bantun F, Alhazmi A, Hakamy A, Kaabi YA, Samlan G, Lohani M, Thangavel N, Al-Kasim MA. Human Growth Hormone Fragment 176-191 Peptide Enhances the Toxicity of Doxorubicin-Loaded Chitosan Nanoparticles Against MCF-7 Breast Cancer Cells. Drug Des Devel Ther. 2022 Jun 27;16:1963-1974. . PMID: 35783198; PMCID: PMC9249349.\u003c\/li\u003e\n\u003cli\u003eMoré, M. I., \u0026amp; Kenley, D. (2014). Safety and metabolism of AOD9604, a novel nutraceutical ingredient for improved metabolic health. \u003cem\u003eJournal of Endocrinology and Metabolism\u003c\/em\u003e, \u003cem\u003e4\u003c\/em\u003e(3), 64-77.\u003c\/li\u003e\n\u003cli\u003eKwon DR, Park GY. Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model. Ann Clin Lab Sci. 2015 Summer;45(4):426-32. PMID: 26275694.\u003c\/li\u003e\n\u003cli\u003eNg FM, Bornstein J. Hyperglycemic action of synthetic C-terminal fragments of human growth hormone. Am J Physiol. 1978 May;234(5):E521-6. . PMID: 645904.\u003c\/li\u003e\n\u003cli\u003eHeffernan M, Summers RJ, Thorburn A, Ogru E, Gianello R, Jiang WJ, Ng FM. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology. 2001 Dec;142(12):5182-9. . PMID: 11713213.\u003c\/li\u003e\n\u003cli\u003eStier, H., Vos, E., \u0026amp; Kenley, D. (2013). Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans. \u003cem\u003eJournal of Endocrinology and Metabolism\u003c\/em\u003e, \u003cem\u003e3\u003c\/em\u003e(1-2), 7-15.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"author-details\"\u003e\n\u003cp\u003eDr. Usman (BSc, MBBS, MaRCP) completed his studies in medicine at the Royal College of Physicians, London. He is an avid researcher with more than 30 publications in internationally recognized peer-reviewed journals. Dr. Usman has worked as a researcher and a medical consultant for reputable pharmaceutical companies such as Johnson \u0026amp; Johnson and Sanofi.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"mysite","offers":[{"title":"Default Title","offer_id":51786430054717,"sku":"sku2194756127805","price":120.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0997\/4474\/3741\/files\/Frag-176-191-5mg-1.webp?v=1780466171"},{"product_id":"aod9604-5mg","title":"🔥（Weight Management \u0026 Fat Burning）AOD9604 · 5mg","description":"\u003cp\u003e🌟 AOD9604 · 5mg – Lyophilized Peptide Powder 🌟\u003cbr\u003eStrength: 5mg\u003cbr\u003eForm: Lyophilized powder (must be dissolved before injection)\u003cbr\u003eIntended Use: For use as a health supplement via injection\u003cbr\u003e🧬 Product Overview\u003cbr\u003eAOD9604 is a high-purity lyophilized peptide powder administered via subcutaneous injection. It supports the body’s fat metabolism regulation, helps maintain energy balance, and promotes overall physical wellness management. The lyophilized powder form better preserves peptide activity, ensuring more stable and efficient absorption✨\u003cbr\u003e🌱 Key Ingredients\u003cbr\u003e🔹 AOD9604 Active Peptide (5mg)\u003cbr\u003eSupports metabolic balance and energy regulation⚡\u003cbr\u003e🔹 Freeze-Dried Powder Form\u003cbr\u003eFor injection; peptide activity is rapidly absorbed💧\u003c\/p\u003e\n\u003cp\u003e💖 Benefits for the Body\u003cbr\u003e🔥 Supports Body Fat Metabolism\u003cbr\u003eHelps the body utilize stored energy more efficiently, supports a healthy metabolic state, and promotes a lighter, more natural body.\u003cbr\u003e⚡ Boosts Vitality and Energy\u003cbr\u003eHelps alleviate daily fatigue, boosts energy levels, and makes daily life feel more relaxed and energetic.\u003cbr\u003e🔄 Supports Metabolic Balance\u003cbr\u003ePromotes more efficient utilization of nutrients and energy, helping maintain a stable and healthy physical state.\u003cbr\u003e💪 Supports Post-Workout Recovery and Endurance\u003cbr\u003eHelps the body maintain better recovery after exercise, high-intensity training, or work, enhancing endurance and vitality.\u003cbr\u003e🩹 Supports Tissue and Overall Health\u003cbr\u003eHelps maintain the health of bodily tissues and cells, promoting overall balance and the body’s ability to recover.\u003cbr\u003e🌿 Supports Overall Wellness Management\u003cbr\u003eSupports a healthy lifestyle, helping the body maintain a more stable and natural state.\u003cbr\u003e❤️ Holistic Health Support\u003cbr\u003eAssists in the coordinated functioning of the body’s systems, helping to maintain long-term health, balance, and vitality.\u003c\/p\u003e\n\u003cp\u003e💉 Usage Recommendations (Injection)\u003cbr\u003eDissolve the lyophilized powder according to the instructions and administer via subcutaneous injection (subcutaneous injection)\u003cbr\u003eRecommended for use in conjunction with a regular sleep schedule, healthy diet, and moderate exercise\u003cbr\u003eRotate injection sites (abdomen, outer thigh, or outer upper arm)\u003cbr\u003eMaintain aseptic technique before and after use to ensure hygiene and safety\u003c\/p\u003e\n\u003cp\u003e❄️ Storage Instructions\u003cbr\u003eStore unused lyophilized powder in the refrigerator (2–8°C)\u003cbr\u003eAvoid direct sunlight and high temperatures\u003cbr\u003eUse as soon as possible after reconstitution, following the instructions\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eAOD9604\u003c\/strong\u003e\u003cspan\u003e \u003c\/span\u003eis a synthetic peptide fragment used in laboratory research to study metabolic signaling, adipose tissue biology, and related experimental models. This product is supplied strictly for research use only. \u003c\/p\u003e\n\u003cp\u003eFor laboratory and analytical consistency, AOD9604 5 mg is typically supplied as a\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003ehigh-purity peptide\u003c\/strong\u003e, manufactured under controlled conditions. Research batches are produced as\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003eLPS-free and endotoxin-free peptides\u003c\/strong\u003e, with\u003cspan\u003e \u003c\/span\u003e\u003cstrong\u003eresearch peptide endotoxin testing\u003c\/strong\u003e\u003cspan\u003e \u003c\/span\u003eperformed to support reliability in sensitive experimental systems. These quality parameters are especially relevant in studies where inflammatory signaling or immune interference must be carefully controlled.\u003c\/p\u003e\n\u003csection class=\"reconstitution-section\"\u003e\n\u003cdiv class=\"container-new\"\u003e\n\u003cdiv class=\"text-lg-center mb-4\"\u003e\n\u003ch2 class=\"recon-title\"\u003eReconstitution Guide\u003c\/h2\u003e\n\u003cp class=\"recon-subtitle\"\u003eStandard reconstitution protocol for lyophilized AOD9604 5mg using bacteriostatic water.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"row g-5\"\u003e\n\u003cdiv class=\"col-lg-4\"\u003e\n\u003cdiv class=\"recon-card\"\u003e\n\u003cdiv class=\"recon-step\"\u003e[1]\u003c\/div\u003e\n\u003ch4\u003ePrepare Aseptic Environment\u003c\/h4\u003e\n\u003cp\u003eEnsure all equipment is sterile. Work under aseptic conditions — laminar flow hood preferred. Swab both vial stoppers with 70% isopropyl alcohol and allow to fully air-dry before puncturing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"col-lg-4\"\u003e\n\u003cdiv class=\"recon-card\"\u003e\n\u003cdiv class=\"recon-step\"\u003e[2]\u003c\/div\u003e\n\u003ch4\u003eReconstitute with BAC Water\u003c\/h4\u003e\n\u003cp\u003eUsing a sterile syringe, draw the calculated volume of bacteriostatic water. Inject slowly into the AOD9604 5mg vial along the glass wall. Do not shake. Gently swirl until fully dissolved.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"col-lg-4\"\u003e\n\u003cdiv class=\"recon-card\"\u003e\n\u003cdiv class=\"recon-step\"\u003e[3]\u003c\/div\u003e\n\u003ch4\u003eStore and Document\u003c\/h4\u003e\n\u003cp\u003eReconstituted AOD9604 5mg should be stored at 2–8°C and used within 28 days. Discard immediately if cloudiness or particulates appear. Unopened lyophilized vials remain stable at -20°C for up to 24 months.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"recon-note\"\u003e\n\u003cbr\u003e\n\u003cdiv\u003e\n\u003cstrong\u003eEndotoxin Note:\u003c\/strong\u003e\u003cspan\u003e \u003c\/span\u003eAOD9604 5mg is endotoxin-screened at the compound level. Full LAL test results available in the product COA.\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"vendor-section\"\u003e\n\u003cdiv class=\"container-new\"\u003e\n\u003cspan class=\"vendor-tag\"\u003eVendor Comparison\u003c\/span\u003e\n\u003ch2 class=\"vendor-title\"\u003eWhy Researchers Choose Licensed Peptides\u003c\/h2\u003e\n\u003cp class=\"vendor-subtitle\"\u003eNot all peptide vendors hold themselves to the same verification standards.\u003c\/p\u003e\n\u003cdiv class=\"table-responsive vendor-table-wrap\"\u003e\n\u003ctable class=\"table vendor-table align-middle\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth scope=\"col\"\u003eVerification Standard\u003c\/th\u003e\n\u003cth class=\"lp-col\" scope=\"col\"\u003eLicensed Peptides\u003c\/th\u003e\n\u003cth class=\"gv-col\" scope=\"col\"\u003eGeneric Vendors\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHPLC Purity Analysis\u003c\/td\u003e\n\u003ctd class=\"lp-col\"\u003e\n\u003cimg alt=\"✓\" src=\"https:\/\/licensedpeptides.com\/wp-content\/themes\/Avada-Child-Theme\/assets-new\/images\/table_tick.svg\" loading=\"lazy\"\u003e\u003cspan\u003e \u003c\/span\u003e99%+ Every Batch\u003c\/td\u003e\n\u003ctd class=\"gv-col\"\u003e\n\u003cimg alt=\"✗\" src=\"https:\/\/licensedpeptides.com\/wp-content\/themes\/Avada-Child-Theme\/assets-new\/images\/table-cross.svg\" loading=\"lazy\"\u003e\u003cspan\u003e \u003c\/span\u003eOften Not Disclosed\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMass Spectrometry Identity\u003c\/td\u003e\n\u003ctd class=\"lp-col\"\u003e\n\u003cimg alt=\"✓\" src=\"https:\/\/licensedpeptides.com\/wp-content\/themes\/Avada-Child-Theme\/assets-new\/images\/table_tick.svg\" loading=\"lazy\"\u003e\u003cspan\u003e \u003c\/span\u003eSequence Confirmed\u003c\/td\u003e\n\u003ctd class=\"gv-col\"\u003e\n\u003cimg alt=\"✗\" src=\"https:\/\/licensedpeptides.com\/wp-content\/themes\/Avada-Child-Theme\/assets-new\/images\/table-cross.svg\" loading=\"lazy\"\u003e\u003cspan\u003e \u003c\/span\u003eRarely Available\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEndotoxin Screening (LAL)\u003c\/td\u003e\n\u003ctd class=\"lp-col\"\u003e\n\u003cimg alt=\"✓\" src=\"https:\/\/licensedpeptides.com\/wp-content\/themes\/Avada-Child-Theme\/assets-new\/images\/table_tick.svg\" loading=\"lazy\"\u003e\u003cspan\u003e \u003c\/span\u003eEvery Product\u003c\/td\u003e\n\u003ctd class=\"gv-col\"\u003e\n\u003cimg alt=\"✗\" src=\"https:\/\/licensedpeptides.com\/wp-content\/themes\/Avada-Child-Theme\/assets-new\/images\/table-cross.svg\" loading=\"lazy\"\u003e\u003cspan\u003e \u003c\/span\u003eIndustry Exception\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGMP-Certified USA Manufacture\u003c\/td\u003e\n\u003ctd class=\"lp-col\"\u003e\n\u003cimg alt=\"✓\" src=\"https:\/\/licensedpeptides.com\/wp-content\/themes\/Avada-Child-Theme\/assets-new\/images\/table_tick.svg\" loading=\"lazy\"\u003e\u003cspan\u003e \u003c\/span\u003eISO 9001:2015\u003c\/td\u003e\n\u003ctd class=\"gv-col\"\u003e\n\u003cimg alt=\"✗\" src=\"https:\/\/licensedpeptides.com\/wp-content\/themes\/Avada-Child-Theme\/assets-new\/images\/table-cross.svg\" loading=\"lazy\"\u003e\u003cspan\u003e \u003c\/span\u003eOften Overseas\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCOA Published \u0026amp; Downloadable\u003c\/td\u003e\n\u003ctd class=\"lp-col\"\u003e\n\u003cimg alt=\"✓\" src=\"https:\/\/licensedpeptides.com\/wp-content\/themes\/Avada-Child-Theme\/assets-new\/images\/table_tick.svg\" loading=\"lazy\"\u003e\u003cspan\u003e \u003c\/span\u003eEvery Lot\u003c\/td\u003e\n\u003ctd class=\"gv-col\"\u003e\n\u003cimg alt=\"✗\" src=\"https:\/\/licensedpeptides.com\/wp-content\/themes\/Avada-Child-Theme\/assets-new\/images\/table-cross.svg\" loading=\"lazy\"\u003e\u003cspan\u003e \u003c\/span\u003eInconsistent\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSame-Day USA Fulfillment\u003c\/td\u003e\n\u003ctd class=\"lp-col\"\u003e\n\u003cimg alt=\"✓\" src=\"https:\/\/licensedpeptides.com\/wp-content\/themes\/Avada-Child-Theme\/assets-new\/images\/table_tick.svg\" loading=\"lazy\"\u003e\u003cspan\u003e \u003c\/span\u003eBefore 4PM PST\u003c\/td\u003e\n\u003ctd class=\"gv-col\"\u003e\n\u003cimg alt=\"✗\" src=\"https:\/\/licensedpeptides.com\/wp-content\/themes\/Avada-Child-Theme\/assets-new\/images\/table-cross.svg\" loading=\"lazy\"\u003e\u003cspan\u003e \u003c\/span\u003e3-10 Day Lead Time\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"faq-section\"\u003e\n\u003cdiv class=\"container-new\"\u003e\n\u003cdiv class=\"text-lg-center\"\u003e\n\u003cspan class=\"faq-tag\"\u003eResearch Questions\u003c\/span\u003e\n\u003ch2 class=\"faq-title\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"row justify-content-center\"\u003e\n\u003cdiv class=\"col-md-8\"\u003e\n\u003cdiv class=\"faq-wrap\"\u003e\n\u003cdiv id=\"faqAccordion\" class=\"accordion faq-accordion\"\u003e\n\u003cdiv class=\"accordion-item\"\u003e\n\u003ch2 id=\"faqHeading_0\" class=\"accordion-header\"\u003e\u003cbutton aria-controls=\"faqCollapse_0\" aria-expanded=\"true\" data-bs-target=\"#faqCollapse_0\" data-bs-toggle=\"collapse\" type=\"button\" class=\"accordion-button faq-button\"\u003e\u003cspan class=\"faq-q\"\u003e1. What is AOD9604?\u003c\/span\u003e\u003cspan aria-hidden=\"true\" class=\"faq-icon\"\u003e\u003ci class=\"fa-solid fa-chevron-down\"\u003e\u003c\/i\u003e\u003c\/span\u003e\u003c\/button\u003e\u003c\/h2\u003e\n\u003cdiv data-bs-parent=\"#faqAccordion\" aria-labelledby=\"faqHeading_0\" class=\"accordion-collapse collapse show\" id=\"faqCollapse_0\"\u003e\n\u003cdiv class=\"accordion-body faq-body\"\u003e\n\u003cp\u003eAOD9604 is used by researchers as a tool compound in laboratory studies of metabolic and adipose tissue pathways. It is supplied strictly for research use only \u003c\/p\u003e\n\u003ch2 id=\"faqHeading_2\" class=\"accordion-header\"\u003e\u003cbutton aria-controls=\"faqCollapse_2\" aria-expanded=\"true\" data-bs-target=\"#faqCollapse_2\" data-bs-toggle=\"collapse\" type=\"button\" class=\"accordion-button faq-button\"\u003e\u003cspan class=\"faq-q\"\u003e3. What does “LPS-free peptide” mean for AOD9604 5 mg?\u003c\/span\u003e\u003cspan aria-hidden=\"true\" class=\"faq-icon\"\u003e\u003ci class=\"fa-solid fa-chevron-down\"\u003e\u003c\/i\u003e\u003c\/span\u003e\u003c\/button\u003e\u003c\/h2\u003e\n\u003cdiv data-bs-parent=\"#faqAccordion\" aria-labelledby=\"faqHeading_2\" class=\"accordion-collapse collapse show\" id=\"faqCollapse_2\"\u003e\n\u003cdiv class=\"accordion-body faq-body\"\u003e\n\u003cp\u003eLPS-free indicates that the AOD9604 peptide has been manufactured to minimize lipopolysaccharide contamination, which can otherwise interfere with metabolic or inflammatory research data.\u003c\/p\u003e\n\u003ch2 id=\"faqHeading_3\" class=\"accordion-header\"\u003e\u003cbutton aria-controls=\"faqCollapse_3\" aria-expanded=\"true\" data-bs-target=\"#faqCollapse_3\" data-bs-toggle=\"collapse\" type=\"button\" class=\"accordion-button faq-button\"\u003e\u003cspan class=\"faq-q\"\u003e4. Why is endotoxin-free status important in AOD9604 research applications?\u003c\/span\u003e\u003cspan aria-hidden=\"true\" class=\"faq-icon\"\u003e\u003ci class=\"fa-solid fa-chevron-down\"\u003e\u003c\/i\u003e\u003c\/span\u003e\u003c\/button\u003e\u003c\/h2\u003e\n\u003cdiv data-bs-parent=\"#faqAccordion\" aria-labelledby=\"faqHeading_3\" class=\"accordion-collapse collapse show\" id=\"faqCollapse_3\"\u003e\n\u003cdiv class=\"accordion-body faq-body\"\u003e\n\u003cp\u003eAn endotoxin-free peptide helps ensure that observed experimental outcomes are attributable to the peptide itself rather than unintended immune or inflammatory responses caused by endotoxin contamination.\u003c\/p\u003e\n\u003ch2 id=\"faqHeading_4\" class=\"accordion-header\"\u003e\u003cbutton aria-controls=\"faqCollapse_4\" aria-expanded=\"true\" data-bs-target=\"#faqCollapse_4\" data-bs-toggle=\"collapse\" type=\"button\" class=\"accordion-button faq-button\"\u003e\u003cspan class=\"faq-q\"\u003e5. Is AOD9604 5 mg tested for endotoxins before release?\u003c\/span\u003e\u003cspan aria-hidden=\"true\" class=\"faq-icon\"\u003e\u003ci class=\"fa-solid fa-chevron-down\"\u003e\u003c\/i\u003e\u003c\/span\u003e\u003c\/button\u003e\u003c\/h2\u003e\n\u003cdiv data-bs-parent=\"#faqAccordion\" aria-labelledby=\"faqHeading_4\" class=\"accordion-collapse collapse show\" id=\"faqCollapse_4\"\u003e\n\u003cdiv class=\"accordion-body faq-body\"\u003e\n\u003cp\u003eYes, research peptides such as AOD9604 5 mg are endotoxin tested to meet laboratory standards, supporting reproducibility and consistency in controlled research environments.\u003c\/p\u003e\n\u003ch2 id=\"faqHeading_5\" class=\"accordion-header\"\u003e\u003cbutton aria-controls=\"faqCollapse_5\" aria-expanded=\"true\" data-bs-target=\"#faqCollapse_5\" data-bs-toggle=\"collapse\" type=\"button\" class=\"accordion-button faq-button\"\u003e\u003cspan class=\"faq-q\"\u003e6. What does high purity mean for AOD9604 5 mg as a research peptide?\u003c\/span\u003e\u003cspan aria-hidden=\"true\" class=\"faq-icon\"\u003e\u003ci class=\"fa-solid fa-chevron-down\"\u003e\u003c\/i\u003e\u003c\/span\u003e\u003c\/button\u003e\u003c\/h2\u003e\n\u003cdiv data-bs-parent=\"#faqAccordion\" aria-labelledby=\"faqHeading_5\" class=\"accordion-collapse collapse show\" id=\"faqCollapse_5\"\u003e\n\u003cdiv class=\"accordion-body faq-body\"\u003e\n\u003cp\u003eHigh purity refers to the peptide’s compositional integrity, ensuring minimal presence of synthesis byproducts or contaminants, which is essential for accurate biochemical and molecular research analyses.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"mysite","offers":[{"title":"10 Vials","offer_id":51786432741693,"sku":null,"price":250.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0997\/4474\/3741\/files\/AOD9604-compressed.jpg?v=1780466214"}],"url":"https:\/\/carmonapettoys.shop\/collections\/hot-sale-%e5%89%af%e6%9c%ac.oembed","provider":"ISRAEL ISAIAH SCOTT","version":"1.0","type":"link"}